Alpha-1 antitrypsin (AAT) RNAi materials, compositions comprising AAT RNAi materials, and methods of use

Novel AAT RNAi substances target and inhibit AAT gene expression to prevent and reverse liver damage from AATD by reducing Z-AAT protein accumulation, addressing the inefficacies of existing therapies.

CN119082104APending Publication Date: 2024-12-06ARROWHEAD PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410871205.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-12-08
Filing Date
2018-01-10
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

There is a lack of clinically approved therapies to prevent or slow down the progression of liver diseases caused by alpha-1 antitrypsin deficiency (AATD), and existing RNAi substances for inhibiting AAT gene expression are not efficient or safe enough to selectively target and reduce Z-AAT protein accumulation, leading to liver damage.

Method used

Development of novel AAT-specific RNAi substances with specific sense and antisense strands that target the AAT gene at a defined position, administered with delivery vehicles to inhibit AAT gene expression and reduce Z-AAT protein accumulation, thereby preventing and reversing liver damage.

Benefits of technology

The AAT RNAi substances effectively inhibit AAT gene expression, reducing liver damage and fibrosis, and potentially reversing conditions such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma by targeting Z-AAT protein accumulation in hepatocytes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004921699160000331
    Figure BDA0004921699160000331
  • Figure BDA0004921699160000341
    Figure BDA0004921699160000341
  • Figure BDA0004921699160000361
    Figure BDA0004921699160000361
Patent Text Reader

Abstract

RNAi materials for inhibiting the alpha-1 antitrypsin (AAT) gene, compositions comprising AAT RNAi materials, and methods of use are described. Also disclosed are pharmaceutical compositions comprising one or more AAT RNAi substances and one or more excipients capable of delivering the one or more RNAi substances to hepatocytes in vivo. Delivery of one or more AAT RNAi substances to hepatocytes in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency, such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, elevated transaminase, cholestasis, fibrosis and outbreak liver failure.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 444,452 filed on January 10, 2017, U.S. Provisional Patent Application Serial No. 62 / 486,720 filed on April 18, 2017, and U.S. Provisional Patent Application Serial No. 62 / 596,232 filed on December 8, 2017, the contents of each of which are incorporated herein by reference in their entirety. Field of the Invention

[0003] Disclosed are RNA interference (RNAi) agents for inhibiting alpha-1 antitrypsin gene expression, compositions comprising alpha-1 antitrypsin RNAi agents, and methods of using the same. background

[0005] Alpha-1 antitrypsin (AAT, alpha 1-antitrypsin or A1AT) deficiency is an inherited autosomal dominant disorder that results in misfolding of the AAT protein and inadequate secretion of the misfolded protein, causing lung and liver disease. AAT deficiency (AATD) occurs in approximately 1 in 1,500-3,500 people and often affects people of European ancestry.

[0006] Alpha-1 antitrypsin is a protease inhibitor belonging to the serine superfamily. Conventional AAT protein is a circulating glycoprotein protease inhibitor that is synthesized primarily in the liver by hepatocytes and secreted into the blood. The known physiological function of AAT is to inhibit neutrophil proteases, which play a role in protecting host tissues from nonspecific damage during inflammation.

[0007] The most clinically significant form of the genetic disorder AATD associated with liver disease in children and adults and lung disease in adults is caused by the Z mutation. Through a single point mutation, the Z mutant allele (PiZ) predisposes the mutant Z-type AAT protein ("Z-AAT protein") to abnormal folding causing intracellular retention. The mutant Z-AAT protein monomers are able to form chains of polymers that accumulate into aggregates, sometimes referred to as "globules". The misfolded Z-AAT protein is ineffective throughout the secretory pathway, but instead aggregates and accumulates in the endoplasmic reticulum (ER) of hepatocytes. Aggregate globules stimulate the ER and trigger persistent hepatocellular damage, leading to fibrosis, cirrhosis, and an increased risk of hepatocellular carcinoma. In addition, the lack of circulating antiprotease activity renders the lungs susceptible to damage by neutrophil elastase, leading to the development of respiratory complications such as emphysema.

[0008] Individuals with homozygous PiZZ genotypes are severely deficient in ATT, which leads to lung disease. Weekly AAT enhancement therapy is used, using purified human ATT, to produce AAT close to normal plasma levels in patients with AATD, and to help prevent lung damage in affected individuals. However, although the administration of purified AAT can alleviate or help prevent lung damage caused by the absence of endogenous secretory AAT, AATD patients are still susceptible to the attack of endoplasmic reticulum liver storage diseases caused by the deposition and accumulation of too many abnormally folded AAT proteins. The Z-AAT protein accumulated in the spherical conformation in hepatocytes is a well-known feature of AATD liver disease and is considered to cause proteotoxic effects, which are responsible for inducing liver damage in individuals with AATD, including hepatocyte damage and death and savage liver damage. (See, for example, D. Lindblad et al., Hepatology 2007, 46: 1228-1235). Patients with AATD often develop liver diseases, which may be serious or fatal, and even appear in infancy. Clinical manifestations of liver damage include chronic hepatitis, cirrhosis, hepatocellular carcinoma, elevated transaminases (transaminitis), cholestasis, fibrosis, and even fulminant hepatic failure.

[0009] There is currently a lack of clinically approved therapies to prevent the onset of liver diseases caused by AATD or to slow down their progression. In addition, although U.S. Patent Application Publication No. 2015 / 0361427 discloses certain RNAi substances capable of inhibiting ATT gene expression, there is still a need for such novel and efficient AAT RNAi substances, which have improved efficacy and can selectively, efficiently and safely inhibit the expression of AAT genes, thereby preventing and possibly reversing liver damage and fibrosis associated with Z-AAT accumulation. Similarly, although U.S. Patent Application No. 2015 / 0011607 ("Brown'607") belonging to Brown et al. discloses various sequences for inhibiting AAT gene expression, Brown teaches the use of longer double-stranded constructs (referred to as DsiRNA in Brown), and has found that compared to 19-23 polymerized siRNA substances, it will produce "unexpected effective results in terms of efficacy and duration" according to Brown. (See, for example,

[0376] paragraph of Brown'607). In addition, many of the sequences disclosed in Brown '607 are designed to be used in DsiRNA constructs designed to target different positions of AAT mRNA compared to the sequences disclosed in the present invention. Such differences result in different binding affinities for AAT mRNA and produce different cleavage sites, which can affect the inhibitory effect of the compound while potentially causing additional off-target problems (see, e.g., Piotr J. Kamola et al., PLoS Comput Biol, 2015, 11 (12): e1004656 Figure 1 (illustrating the mechanism of siRNA-mediated gene silencing)). For example, there is nothing in Brown '607 that teaches or suggests the design of such (any length) RNAi agents in which the 5' terminal nucleobase or nucleotide of the antisense strand will be aligned with the position 19 nucleotides downstream (towards the 3' end) of position 1000 on the AAT gene (SEQ ID NO: 1). Regardless of the differences between the two, and again only as an example of one such potential AAT RNAi agent sequence, Brown '607 does not teach or suggest the design of such an RNAi agent, wherein the 5' terminal nucleobase of the antisense strand of the RNAi agent corresponds to position 1018 on the AAT gene (SEQ ID NO: 1). In addition, Brown '607 does not teach or suggest the modified AAT RNAi agent constructs disclosed herein. Summary of the invention

[0010] There is a need for novel AAT-specific RNA interference (RNAi) substances (also referred to herein as RNAi substances, RNAi initiators or initiators) that can selectively and efficiently inhibit AAT gene expression. In addition, there is a need for compositions of novel AAT-specific RNAi substances for treating diseases associated with AAT deficiency.

[0011] Because liver damage caused by AATD occurs through a gain-of-function mechanism, inhibition of AAT gene expression can be used to prevent the accumulation of Z-AAT protein in the liver. In addition, the reduction or removal of Z-AAT aggregates reduces ER stress in hepatocytes and provides additional advantages in reducing the likelihood of liver cell damage and assisting in the treatment of liver cell damage and chronic liver damage (such as fibrosis, cirrhosis, hepatocellular carcinoma and other conditions and diseases caused by AATD). Reducing the inflammatory Z-AAT protein, which has been clearly defined as the cause of progressive liver disease in AATD patients, is very important because it can slow or stop the progression of liver disease and allow fibrotic tissue to repair.

[0012] In summary, the present disclosure features novel AAT RNAi substances, compositions comprising AAT RNAi substances, and methods of using AAT RNAi substances and compositions comprising AAT RNAi substances to inhibit the expression of AAT genes in vivo and / or in vitro. Methods of treating AATD-related diseases using the AAT RNAi substances and compositions comprising AAT RNAi substances described herein are also described herein.

[0013] The AAT RNAi substances and methods disclosed herein can be used for the treatment of AATD, including the treatment of conditions and diseases caused by AATD, such as chronic hepatitis, cirrhosis, hepatocellular carcinoma and fulminant liver failure. When the AAT RNAi substances disclosed herein are administered to a subject, liver damage and fibrosis associated with Z-AAT accumulation can be prevented and / or reversed. The AAT RNAi substances shown herein can be administered to a subject, e.g., a human or animal subject, by any suitable method known in the art, such as subcutaneous injection or intravenous administration.

[0014] In one aspect, the disclosure features an RNAi substance for inhibiting the expression of an alpha-1 antitrypsin (AAT) gene, wherein the RNAi substance comprises a sense strand and an antisense strand. Also described herein are RNAi substances capable of inhibiting the expression of an alpha-1 antitrypsin gene, wherein the RNAi substance comprises a sense strand and an antisense strand, and at least one pharmaceutically acceptable excipient.

[0015] Each AAT RNAi material described herein comprises a sense strand and an antisense strand. The sense strand and the antisense strand may be partially, substantially or completely complementary to each other. The length of the sense and antisense strands of the RNAi material described herein may be 16-30 nucleotides. In some embodiments, the length of the sense and antisense strands is independently 17-26 nucleotides. In some embodiments, the length of the sense and antisense strands is independently 21-26 nucleotides. In some embodiments, the length of the sense and antisense strands is independently 21-24 nucleotides. In some embodiments, the length of the sense and / or antisense strands is independently 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides. The sense and antisense strands may be the same length or different lengths. The RNAi material described herein inhibits the in vivo or in vitro expression of one or more AAT genes after being delivered to cells expressing AAT.

[0016] The AAT RNAi substance comprises a sense strand (also referred to as a trailing strand) and an antisense strand (also referred to as a guide strand). The sense strand of the AAT RNAi substance described herein comprises a nucleotide sequence having at least 85% identity to a core stretch of at least 16 consecutive nucleotides of a sequence in AAT mRNA. In some embodiments, the length of the sense strand core stretch having at least 85% identity to a sequence in AAT mRNA is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides. The antisense strand of the AAT RNAi substance comprises a nucleotide sequence having at least 85% complementarity to a core stretch of at least 16 consecutive nucleotides of a sequence in AAT mRNA and a corresponding sense strand. In some embodiments, the length of the antisense strand core stretch having at least 85% complementarity to a sequence in AAT mRNA or a corresponding sense strand is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides.

[0017] In some embodiments, the AAT RNAi agents disclosed herein target a portion of the AAT gene having a sequence of any one of the sequences disclosed in Table 1.

[0018] Examples of AAT RNAi agent sense and antisense strands that can be used in AAT RNAi agents are provided in Tables 2, 3, 4, and 5. Examples of duplexes containing AAT RNAi agents are provided in Table 6. Examples of RNAi agent 19 nucleotide core segment sequences that may constitute or be contained in the sense and antisense strands of certain AAT RNAi agents disclosed herein are provided in Table 2.

[0019] In another aspect, the disclosure features methods for in vivo delivery of AAT RNAi agents to liver cells of a subject (e.g., a mammal). In some embodiments, one or more AAT RNAi agents are delivered to target cells or tissues using any oligonucleotide delivery technology known in the art. Nucleic acid delivery methods include, but are not limited to, encapsulation in liposomes, iontophoresis, or incorporation into other carriers such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres, proteinaceous carriers, or Dynamic Polyconjugates. TM (DPC) (see, e.g., WO 2000 / 053722, WO 2008 / 0022309, WO 2011 / 104169, and WO 2012 / 083185, each of which is incorporated herein by reference). In some embodiments, the AAT RNAi agents disclosed herein can be used in conjunction with a delivery vehicle, such as a polymer, an amphiphilic polymer, a membrane active polymer, a peptide, such as melittin or a melittin-like peptide, a reversibly modified polymer or peptide, or a lipid.

[0020] In some embodiments, the AAT RNAi substance is delivered to a target cell or tissue by covalently linking or coupling the RNAi substance to a targeting group such as an asialoglycoprotein receptor ligand. In some embodiments, the asialoglycoprotein receptor ligand includes, is composed of, or is substantially composed of: a galactose or galactose derivative cluster. In some embodiments, the AAT RNAi substance is connected to a targeting ligand comprising galactose-derived N-acetyl-galactosamine. In some embodiments, the galactose derivative cluster comprises an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer. In some embodiments, the galactose-derived cluster is an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer. For example, exemplary targeting groups that can be used to deliver the disclosed RNAi substance are described in U.S. Patent Application Nos. 15 / 452,324 and WO 2017 / 156012, the entire contents of which are incorporated herein by reference.

[0021] The targeting group can be connected to the 3' or 5' end of the sense strand or antisense strand of the AAT RNAi material. In some embodiments, the targeting group is connected to the 3' or 5' end of the sense strand. In some embodiments, the targeting group is connected to the 5' end of the sense strand. In some embodiments, the targeting group is connected to the nucleotide interior on the sense strand and / or antisense strand of the RNAi material. In some embodiments, the targeting group is connected to the RNAi material via a joint.

[0022] A targeting group with or without a linker can be attached to the 5' or 3' end of any of the sense and / or antisense strands disclosed in Tables 2, 3, 4, and 5. A linker with or without a targeting group can be attached to the 5' or 3' end of any of the sense and / or antisense strands disclosed in Tables 2, 3, 4, and 5.

[0023] In another aspect, the disclosure features compositions comprising one or more AAT RNAi agents having a duplex structure disclosed in Table 6.

[0024] In some embodiments, described herein is such a composition, the composition comprises a combination or mixture of at least two AAT RNAi substances with different nucleotide sequences. In some embodiments, two or more different AAT RNAi substances are each separated and independently connected to a targeting group. In some embodiments, two or more different AAT RNAi substances are each connected to a targeting group comprising a targeting ligand or consisting of a targeting ligand, and the targeting ligand comprises one or more parts of a targeting asialoglycoprotein receptor. In some embodiments, two or more different AAT RNAi substances are each connected to a targeting group comprising a targeting ligand or consisting of a targeting ligand, and the targeting ligand comprises one or more galactose derivatives. In some embodiments, two or more different AAT RNAi substances are each connected to a targeting group comprising a targeting ligand or consisting of a targeting ligand, and the targeting ligand comprises one or more N-acetyl-galactosamine. In some embodiments, when two or more RNAi substances are included in the composition, each RNAi substance is independently connected to the same targeting group. In some embodiments, when two or more RNAi substances are included in the composition, each RNAi substance is independently connected to different targeting groups, such as targeting groups with different chemical structures.

[0025] In some embodiments, the targeting group is connected to the AAT RNAi substance without using an additional joint. In some embodiments, the targeting group is designed to have such a joint, the presence of which is easy to promote connection with the AAT RNAi substance. In some embodiments, when two or more RNAi substances are included in the composition, the two or more RNAi substances can be connected to their corresponding targeting groups using the same joint. In some embodiments, when two or more RNAi substances are included in the composition, the two or more RNAi substances are connected to their corresponding targeting groups using different joints.

[0026] In another aspect, the disclosure features a method for inhibiting alpha-1 antitrypsin gene expression in a subject, the method comprising administering to the subject an amount of an AAT RNAi agent capable of inhibiting AAT gene expression, wherein the AAT RNAi agent comprises a sense strand and an antisense strand.

[0027] Also described herein are methods for treating a condition or disease caused by AATD, comprising administering to a subject a therapeutically effective amount of an RNAi agent described herein. Also described are methods for inhibiting AAT gene expression, wherein the method comprises administering to a cell an AAT RNAi agent described herein.

[0028] In some embodiments, disclosed herein is a method for treating AATD (including treating a condition or disease caused by AATD), the method comprising administering to a subject a therapeutically effective amount of an RNAi agent, wherein the RNAi agent has a sense strand, wherein the sense strand contains a sequence of any one of the sequences shown in Tables 2, 3 or 4.

[0029] In some embodiments, disclosed herein is a method for inhibiting AAT gene expression, the method comprising administering an AAT RNAi substance to a cell, wherein the AAT RNAi substance comprises an antisense strand, wherein the antisense strand comprises a sequence shown in any one of Tables 2, 3 or 4.

[0030] In some embodiments, disclosed herein is a method for treating AATD (including treating a condition or disease caused by AATD), the method comprising administering to a subject a therapeutically effective amount of an RNAi agent, wherein the RNAi agent comprises a sense strand, wherein the sense strand comprises a sequence of any one of the sequences shown in Tables 2, 3 or 5.

[0031] In some embodiments, disclosed herein is a method for inhibiting AAT gene expression, wherein the method comprises administering to a cell an AAT RNAi substance comprising a sense strand containing a sequence shown in any one of Tables 2, 3 or 5.

[0032] In some embodiments, disclosed herein is a method for treating AATD (including treating a condition or disease caused by AATD), wherein the method comprises administering to a subject a therapeutically effective amount of an RNAi substance, wherein the RNAi substance comprises a sense strand and an antisense strand, wherein the sense strand comprises a sequence of any one of the sequences shown in Table 5, and the antisense strand comprises a sequence of any one of the sequences shown in Table 4.

[0033] In some embodiments, disclosed herein is a method for inhibiting AAT gene expression, wherein the method comprises administering to a subject a therapeutically effective amount of an RNAi substance, wherein the RNAi substance comprises a sense strand and an antisense strand, wherein the sense strand comprises a sequence of any one of the sequences shown in Table 5, and the antisense strand comprises a sequence of any one of the sequences shown in Table 4.

[0034] In some embodiments, disclosed herein is a method for inhibiting AAT gene expression, wherein the method comprises administering to a subject an AAT RNAi substance, wherein the AAT RNAi substance comprises a sense strand and an antisense strand, wherein the sense strand consists of a nucleobase sequence of any one of the sequences shown in Table 5, and the antisense strand consists of a nucleobase sequence of any one of the sequences shown in Table 4. In other embodiments, disclosed herein is a method for inhibiting AAT gene expression, wherein the method comprises administering to a subject an AAT RNAi substance, wherein the AAT RNAi substance comprises a sense strand and an antisense strand, wherein the sense strand consists of a modified sequence of any one of the modified sequences shown in Table 5, and the antisense strand consists of a modified sequence of any one of the modified sequences shown in Table 4.

[0035] In some embodiments, disclosed herein are methods for inhibiting AAT gene expression in a cell, wherein the method comprises administering one or more AAT RNAi substances having a duplex structure shown in Table 6.

[0036] In some embodiments, the AAT RNAi agent disclosed herein has a structure comprising, consisting of, or consisting essentially of the structure shown in any one of Figures 1, 2, 3, 4, 5, 6, 7, or 8.

[0037] The AAT RNAi substances disclosed herein are designed to target a specific position on the AAT gene (SEQ ID NO: 1). As defined herein, the antisense strand sequence is designed to target the gene at a given position on the AAT gene, and when base-paired with the gene, the 5' terminal nucleobase of the antisense strand will be aligned with the position 19 nucleotides downstream (towards the 3' end) of the position on the gene. For example, as shown in Tables 1, 2 and 3 herein, the antisense strand sequence designed to target the AAT gene at position 1000 requires that when base-paired with the gene, the 5' terminal nucleobase of the antisense strand is aligned with position 1018 of the AAT gene. As shown herein, the AAT RNAi agent does not require the nucleobase at position 1 (5′→3′) of the antisense strand to be complementary to the gene, provided that the antisense strand is at least 85% complementary to the gene over a core sequence of at least 16 consecutive nucleotides (e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% complementary). For example, for the AAT RNAi agent disclosed herein that is intended to target position 1000 of the AAT gene, the 5' terminal nucleobase of the antisense strand of the AAT RNAi agent must be aligned with position 1018 of the gene; however, the 5' terminal nucleobase of the antisense strand can, but is not required to, be complementary to position 1018 of the AAT gene, provided that the antisense strand is at least 85% complementary to the gene over a core stretch of at least 16 consecutive nucleotides (e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% complementary). As shown in the various examples disclosed herein, the specific site at which the antisense strand of the AAT RNAi agent binds to the gene (e.g., whether the AAT RNAi agent is designed to target the AAT gene at position 1000, position 1142, or other positions) is very important for the level of inhibition achieved by the AAT RNAi agent.

[0038] In some embodiments, the antisense strand sequence is designed to have the sequence target position 1000 of the AAT gene (SEQ ID NO: 1).

[0039] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCU (SEQ ID NO: 801), wherein at least one or more nucleotides are modified nucleotides. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCU (SEQ ID NO: 801), wherein all or substantially all nucleotides are modified nucleotides.

[0040] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGUU (SEQ ID NO: 794), wherein at least one or more nucleotides are modified nucleotides. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGUU (SEQ ID NO: 794), wherein all or substantially all nucleotides are modified nucleotides.

[0041] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCUU (SEQ ID NO: 839), wherein at least one or more nucleotides are modified nucleotides. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCUU (SEQ ID NO: 839), wherein all or substantially all nucleotides are modified nucleotides.

[0042] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCG (SEQ ID NO: 800), wherein at least one or more nucleotides are modified nucleotides. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCG (SEQ ID NO: 800), wherein all or substantially all nucleotides are modified nucleotides.

[0043] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACG (SEQ ID NO: 80), wherein one or more nucleotides are modified nucleotides. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACG (SEQ ID NO: 80), wherein all or substantially all nucleotides are modified nucleotides.

[0044] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGUUAAACAUGCCUAAACG (SEQ ID NO: 81), wherein one or more nucleotides are modified nucleotides. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGUUAAACAUGCCUAAACG (SEQ ID NO: 81), wherein all or substantially all nucleotides are modified nucleotides.

[0045] In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACA (SEQ ID NO: 429), wherein one or more nucleotides are modified nucleotides. In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACA (SEQ ID NO: 429), wherein all or substantially all nucleotides are modified nucleotides.

[0046] In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACU (SEQ ID NO: 430), wherein one or more nucleotides are modified nucleotides. In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACU (SEQ ID NO: 430), wherein all or substantially all nucleotides are modified nucleotides.

[0047] In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACA (SEQ ID NO:429), wherein one or more nucleotides are modified nucleotides, and the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACG (SEQ ID NO:80), wherein one or more nucleotides are modified nucleotides.

[0048] In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACU (SEQ ID NO: 430), wherein one or more nucleotides are modified nucleotides, and the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGUUAAACAUGCCUAAACG (SEQ ID NO: 81), wherein one or more nucleotides are modified nucleotides.

[0049] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGUU (SEQ ID NO: 794), wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACAUU (SEQ ID NO: 857).

[0050] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCUU (SEQ ID NO: 839), wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence GCGUUUAGGCAUGUUUAACAUU (SEQ ID NO: 885).

[0051] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCG (SEQ ID NO: 800), wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGCGUUUAGGCAUGUUUAACA (SEQ ID NO: 864).

[0052] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCU (SEQ ID NO: 801), wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGCGUUUAGGCAUGUUUAACA (SEQ ID NO: 866).

[0053] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from UGUUAAACAUGCCUAAACGUU (SEQ ID NO:794) by 0, 1, 2, or 3 nucleotides, wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from CGUUUAGGCAUGUUUAACAUU (SEQ ID NO:857) by 0, 1, 2, or 3 nucleotides.

[0054] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from UGUUAAACAUGCCUAAACGCUU (SEQ ID NO: 839) by 0, 1, 2, or 3 nucleotides, wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from GCGUUUAGGCAUGUUUAACAUU (SEQ ID NO: 885) by 0, 1, 2, or 3 nucleotides.

[0055] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from UGUUAAACAUGCCUAAACGCG (SEQ ID NO: 800) by 0, 1, 2, or 3 nucleotides, wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from CGCGUUUAGGCAUGUUUAACA (SEQ ID NO: 864) by 0, 1, 2, or 3 nucleotides.

[0056] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from UGUUAAACAUGCCUAAACGCU (SEQ ID NO:801) by 0, 1, 2, or 3 nucleotides, wherein at least one or more nucleotides are modified nucleotides, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence that differs from AGCGUUUAGGCAUGUUUAACA (SEQ ID NO:866) by 0, 1, 2, or 3 nucleotides.

[0057] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04824.

[0058] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04825.

[0059] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04826.

[0060] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04827.

[0061] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04828.

[0062] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04829.

[0063] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04830.

[0064] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04831.

[0065] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of duplex AD04832.

[0066] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04833.

[0067] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04834.

[0068] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04835.

[0069] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04836.

[0070] In some embodiments, the AAT RNAi agent comprises, consists of, or consists essentially of the duplex structure of AD04837.

[0071] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACG (SEQ ID NO: 80), wherein one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 80 is located at positions 1-19 (5′→3′) of the antisense strand. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACG (SEQ ID NO: 80), wherein all or substantially all nucleotides are modified nucleotides, and wherein SEQ ID NO: 80 is located at positions 1-19 (5′→3′) of the antisense strand.

[0072] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGUUAAACAUGCCUAAACG (SEQ ID NO: 81), wherein one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 81 is located at positions 1-19 (5′→3′) of the antisense strand. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGUUAAACAUGCCUAAACG (SEQ ID NO: 81), wherein all or substantially all nucleotides are modified nucleotides, and wherein SEQ ID NO: 81 is located at positions 1-19 (5′→3′) of the antisense strand.

[0073] In some embodiments, the sense strand of the AAT RNAi agent comprises the nucleobase sequence CGUUUAGGCAUGUUUAACA (SEQ ID NO: 429), wherein one or more nucleotides are modified nucleotides, and wherein position 19 of SEQ ID NO: 429 forms a base pair with a nucleotide at the 5' end of the antisense strand. In some embodiments, the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACA (SEQ ID NO: 429), wherein all or substantially all nucleotides are modified nucleotides, and wherein position 19 of SEQ ID NO: 429 forms a base pair with a nucleotide at the 5' end of the antisense strand.

[0074] In some embodiments, the sense strand of the AAT RNAi agent comprises the nucleobase sequence CGUUUAGGCAUGUUUAACU (SEQ ID NO: 430), wherein one or more nucleotides are modified nucleotides, and wherein position 19 of SEQ ID NO: 430 forms a base pair with a nucleotide at the 5' end of the antisense strand. In some embodiments, the sense strand of the AAT RNAi agent comprises the nucleobase sequence CGUUUAGGCAUGUUUAACU (SEQ ID NO: 430), wherein all or substantially all nucleotides are modified nucleotides, and wherein position 19 of SEQ ID NO: 430 forms a base pair with a nucleotide at the 5' end of the antisense strand.

[0075] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGUU (SEQ ID NO: 794), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 794 is located at positions 1-21 (5′→3′) of the antisense strand. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGUU (SEQ ID NO: 794), wherein all or substantially all nucleotides are modified nucleotides, and wherein SEQ ID NO: 794 is located at positions 1-21 (5′→3′) of the antisense strand.

[0076] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCUU (SEQ ID NO: 839), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 839 is located at positions 1-22 (5′→3′) of the antisense strand. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCUU (SEQ ID NO: 839), wherein all or substantially all nucleotides are modified nucleotides, and wherein SEQ ID NO: 839 is located at positions 1-22 (5′→3′) of the antisense strand.

[0077] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCG (SEQ ID NO: 800), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 800 is located at positions 1-21 (5′→3′) of the antisense strand. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCG (SEQ ID NO: 800), wherein all or substantially all nucleotides are modified nucleotides, and wherein SEQ ID NO: 800 is located at positions 1-21 (5′→3′) of the antisense strand.

[0078] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCU (SEQ ID NO: 801), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 801 is located at positions 1-21 (5′→3′) of the antisense strand. In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCU (SEQ ID NO: 801), wherein all or substantially all nucleotides are modified nucleotides, and wherein SEQ ID NO: 801 is located at positions 1-21 (5′→3′) of the antisense strand.

[0079] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGUU (SEQ ID NO: 794), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO: 794 is located at the 5' end of the antisense strand, and wherein the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGUUUAGGCAUGUUUAACAUU (SEQ ID NO: 857).

[0080] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCUU (SEQ ID NO:839), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:839 is located at the 5' end of the antisense strand, and wherein the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence GCGUUUAGGCAUGUUUAACAUU (SEQ ID NO:885).

[0081] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCG (SEQ ID NO:800), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:800 is located at the 5' end of the antisense strand, and wherein the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence CGCGUUUAGGCAUGUUUAACA (SEQ ID NO:864).

[0082] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence UGUUAAACAUGCCUAAACGCU (SEQ ID NO:801), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:801 is located at the 5' end of the antisense strand, and wherein the sense strand of the AAT RNAi agent comprises or consists of the nucleobase sequence AGCGUUUAGGCAUGUUUAACA (SEQ ID NO:866).

[0083] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from UGUUAAACAUGCCUAAACGUU (SEQ ID NO:794), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:794 is located at the 5' end of the antisense strand, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from CGUUUAGGCAUGUUUAACAUU (SEQ ID NO:857).

[0084] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from UGUUAAACAUGCCUAAACGCUU (SEQ ID NO:839), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:839 is located at the 5' end of the antisense strand, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from GCGUUUAGGCAUGUUUAACAUU (SEQ ID NO:885).

[0085] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from UGUUAAACAUGCCUAAACGCG (SEQ ID NO:800), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:800 is located at the 5' end of the antisense strand, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from CGCGUUUAGGCAUGUUUAACA (SEQ ID NO:864).

[0086] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from UGUUAAACAUGCCUAAACGCU (SEQ ID NO:801), wherein at least one or more nucleotides are modified nucleotides, and wherein SEQ ID NO:801 is located at the 5' end of the antisense strand, and the sense strand of the AAT RNAi agent comprises or consists of a nucleobase sequence having 0, 1, 2, or 3 nucleotide differences from AGCGUUUAGGCAUGUUUAACA (SEQ ID NO:866).

[0087] The AAT RNAi agent described herein may comprise one or more modified nucleotides. The AAT RNAi agent described herein may further comprise one or more phosphorothioate internucleoside linkages.

[0088] The AAT RNAi substances described herein may further comprise one or more targeting groups or linking groups. In some embodiments, the AAT RNAi substances disclosed herein comprise one or more targeting groups. In some embodiments, the targeting group comprises an asialoglycoprotein receptor ligand. In some embodiments, the asialoglycoprotein receptor ligand comprises a galactose or galactose derivative cluster. In some embodiments, the galactose derivative cluster comprises N-acetyl-galactosamine. In some embodiments, the targeting ligand comprises N-acetyl-galactosamine. In some embodiments, the targeting group is coupled to the sense strand of the AAT RNAi substances disclosed herein.

[0089] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsusUfaAfaCfaUfgCfcUfaAfaCfgusu (SEQ ID NO:913), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; and s is a thiophosphate linkage, and the sense strand is at least substantially complementary to the antisense strand.

[0090] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsusUfaAfaCfaUfgCfcUfaAfaCfgcusu (SEQ ID NO:958), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; and s is a phosphorothioate linkage, and the sense strand is at least substantially complementary to the antisense strand.

[0091] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsuUfaAfaCfaUfgCfcUfaAfaCfgsCfsg (SEQ ID NO:959), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; and s is a thiophosphate linkage, and the sense strand is at least substantially complementary to the antisense strand.

[0092] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO:960), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; and s is a thiophosphate linkage, and the sense strand is at least substantially complementary to the antisense strand.

[0093] In some embodiments, the antisense strand of the AAT RNAi comprises or consists of the sequence (5′→3′)usGfsusUfaAfaCfaUfgCfcUfaAfaCfgusu (SEQ ID NO: 913), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)cguuuaGfGfCfauguuuaacausu (SEQ ID NO: 1276), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; wherein optionally present on the sense strand are one, two or more inverted abasic deoxyribose residues (invAb); and wherein optionally linked to the 5′ end of the sense strand is a targeting ligand comprising N-acetyl-galactosamine.

[0094] In some embodiments, the antisense strand of the AAT RNAi comprises or consists of the sequence (5′→3′)usGfsusUfaAfaCfaUfgCfcUfaAfaCfgcusu (SEQ ID NO: 958), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)gcguuuaGfGfCfauguuuaacausu (SEQ ID NO: 1277), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; wherein optionally present on the sense strand are one, two or more inverted abasic deoxyribose residues (invAb); and wherein optionally linked to the 5′ end of the sense strand is a targeting ligand comprising N-acetyl-galactosamine.

[0095] In some embodiments, the antisense strand of the AAT RNAi comprises or consists of the sequence (5′→3′)usGfsuUfaAfaCfaUfgCfcUfaAfaCfgsCfsg (SEQ ID NO:959), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)cgcguuuaGfGfCfauguuuaaca (SEQ ID NO:1278), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; wherein optionally present on the sense strand are one, two or more inverted abasic deoxyribose residues (invAb); and wherein optionally linked to the 5′ end of the sense strand is a targeting ligand comprising N-acetyl-galactosamine.

[0096] In some embodiments, the antisense strand of the AAT RNAi comprises or consists of the sequence (5′→3′)usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO:960), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)agcguuuaGfGfCfauguuuaaca (SEQ ID NO:1279), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; wherein optionally present on the sense strand are one, two or more inverted abasic deoxyribose residues (invAb); and wherein optionally linked to the 5′ end of the sense strand is a targeting ligand comprising N-acetyl-galactosamine.

[0097] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsusUfaAfaCfaUfgCfcUfaAfaCfgusu (SEQ ID NO: 913), and the sense strand of the AAT RNAi agent comprises or consists of (5′→3′)(NAG37)s(invAb)scguuuaGfGfCfauguuuaacausu(invAb) (SEQ ID NO: 914). NO:1028), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; (invAb) is an inverted abasic deoxyribose (invAb); and (NAG37) is a targeting ligand comprising N-acetyl-galactosamine, wherein the N-acetyl-galactosamine has the structure shown in Table 7 herein.

[0098] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsusUfaAfaCfaUfgCfcUfaAfaCfgcusu (SEQ ID NO: 958), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)(NAG37)s(invAb)sgcguuuaGfGfCfauguuuaacausu(invAb) (SEQ ID NO: 959). NO:1030), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; (invAb) is an inverted abasic deoxyribose (invAb); and (NAG37) is a targeting ligand comprising N-acetyl-galactosamine having the structure shown in Table 7 herein.

[0099] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsuUfaAfaCfaUfgCfcUfaAfaCfgsCfsg (SEQ ID NO: 959), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)(NAG37)s(invAb)scgcguuuaGfGfCfauguuuaacas(invAb) (SEQ ID NO: NO:1024), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; (invAb) is an inverted abasic deoxyribose (invAb); and (NAG37) is a targeting ligand comprising N-acetyl-galactosamine having the structure shown in Table 7 herein.

[0100] In some embodiments, the antisense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)usGfsuUfaAfacaugCfcUfaAfaCfgCfsu (SEQ ID NO: 960), and the sense strand of the AAT RNAi agent comprises or consists of the sequence (5′→3′)(NAG37)s(invAb)sagcguuuaGfGfCfauguuuaacas(invAb) (SEQ ID NO: NO:1033), wherein a, c, g and u are 2′-O-methyladenosine, cytidine, guanosine or uridine, respectively; Af, Cf, Gf and Uf are 2′-fluoroadenosine, cytidine, guanosine or uridine, respectively; s is a thiophosphate linkage; (invAb) is an inverted abasic deoxyribose (invAb); and (NAG37) is a targeting ligand comprising N-acetyl-galactosamine having the structure shown in Table 7 herein.

[0101] In some embodiments, the AAT RNAi agents described herein may comprise one or more targeting groups having the structure: (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31) s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), (NAG39)s, as defined in Table 7 herein.

[0102] In some embodiments, the AAT RNAi agent described herein comprises a targeting group at the 5' end of the sense strand, wherein the targeting group has the structure: (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31 )s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), (NAG39)s, as defined in Table 7 herein.

[0103] The AAT RNAi agents disclosed herein can be incorporated into a composition comprising one or more disclosed AAT RNAi agents and at least one pharmaceutically acceptable excipient. In some embodiments, the composition comprising one or more disclosed AAT RNAi agents and at least one pharmaceutically acceptable excipient disclosed herein is a pharmaceutical composition.

[0104] The pharmaceutical compositions comprising one or more AAT RNAi substances can be administered in a number of ways, depending on whether local or systemic treatment is desired. Administration can be, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, subcutaneous (e.g., via an implanted device), and intraparenchymal administration. In some embodiments, the pharmaceutical compositions described herein are administered by subcutaneous injection.

[0105] In some embodiments, the composition comprising one or more disclosed AAT RNAi agents and at least one pharmaceutically acceptable excipient may further comprise one or more other therapeutics or treatments.

[0106] In some embodiments, the compositions described herein comprising one or more AAT RNAi agents are packaged in a kit, container, bag, dispenser, prefilled syringe, or vial. In some embodiments, the compositions described herein are administered parenterally.

[0107] The AAT RNAi agents disclosed herein and compositions comprising the same can be administered to a subject to inhibit the expression of alpha-1 antitrypsin in the subject. In some embodiments, the subject is a human. In some embodiments, the subject is a human who has been diagnosed with AATD.

[0108] In some embodiments, disclosed herein is a method for inhibiting AAT gene expression in a cell, the method administering an AAT RNAi agent having an antisense strand that is at least partially complementary to a portion of an AAT mRNA having any one of the sequences listed in Table 1.

[0109] The AAT RNAi substances disclosed herein and compositions comprising the AAT RNAi substances can be administered to a subject for the treatment of AATD (including conditions or diseases caused by alpha-1 antitrypsin deficiency). Conditions or diseases that can be treated, prevented and / or controlled by administering the AAT RNAi substances disclosed herein and compositions comprising the same include chronic hepatitis, cirrhosis, hepatocellular carcinoma, elevated transaminases, cholestasis, fibrosis, or fulminant hepatic failure.

[0110] As used herein, the terms "oligonucleotide" and "polynucleotide" refer to a polymer of linked nucleosides, each of which may be independently modified or unmodified.

[0111] As used herein, "RNAi material" or "RNAi initiator" refers to a composition containing RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecules that can degrade or inhibit the translation of messenger RNA (mRNA) transcripts of target mRNA in a sequence-specific manner. The RNAi material used herein can be manipulated by an RNA interference mechanism (i.e., by inducing RNA interference by interacting with components of the RNA interference pathway of mammalian cells (RNA-induced silencing complex or RISC)), or by any other mechanism or pathway. Although it is believed that the term RNAi material as used herein is mainly manipulated by an RNA interference mechanism, the disclosed RNAi material is not limited to or constrained by any specific pathway or mechanism of action. The RNAi material disclosed herein comprises a sense strand and an antisense strand, and includes, but is not limited to, short interfering RNA (siRNA), double-stranded RNA (dsRNA), microRNA (miRNA), short hairpin RNA (shRNA), and a Dicer enzyme substrate. The antisense strand of the RNAi material disclosed herein is at least partially complementary to the targeted mRNA (e.g., AAT mRNA). The RNAi material may include one or more modified nucleotides and / or one or more non-phosphodiester linkages.

[0112] As used herein, the terms "silencing," "reducing," "inhibiting," "downregulating," or "knockdown," when referring to the expression of a given gene, mean that the expression of the gene is reduced when the cell, cell population, or tissue is treated with an RNAi agent as described herein, as measured by the level of RNA transcribed from the gene or the level of a polypeptide, protein, or protein subunit translated from mRNA in a cell, cell population, tissue, or subject in which the gene is transcribed, compared to a second cell, cell population, or tissue that has not been so treated.

[0113] The terms "sequence" and "nucleotide sequence" as used herein refer to the order or sequence of nucleobases or nucleotides described by a sequence of letters using standard nomenclature.

[0114] As used herein, "base", "nucleotide base" or "nucleobase" is a heterocyclic pyrimidine or purine compound that is a standard component of all nucleic acids and includes bases that form adenosine (A), guanosine (G), cytidine (C), thymidine (T) and uracil (U). Nucleobases can be further modified to include, but are not limited to, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases and fluorobases. The term "nucleotide" as used herein may include modified nucleotides (e.g., nucleotide mimetics, abasic residues (Ab) or alternative substitution moieties.

[0115] As used herein and unless otherwise indicated, the term "complementary" is used to describe a first nuclear base or nucleotide sequence (e.g., RNAi material positive strand or targeting mRNA) relative to a second nuclear base or nucleotide sequence (e.g., RNAi material antisense strand or single-stranded antisense oligonucleotide), indicating that an oligonucleotide or polynucleotide comprising a first nucleotide sequence hybridizes (forms base pair hydrogen bonds under mammalian physiological conditions (or similar in vitro environments)) and forms a duplex or double helix structure under specific conditions with an oligonucleotide or polynucleotide comprising a second nucleotide sequence. Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs, and include natural or modified nucleotides or nucleotide mimetics, at least to the extent that the above hybridization requirements are met. Sequence identity or complementarity is independent of modification. For example, for the purpose of identifying identity or complementarity, a and Af defined herein are complementary to U (or T) and identical to A.

[0116] As used herein, "perfect complementarity" or "complete complementarity" means that all (100%) of the nucleobases or nucleotides in the contiguous sequence of the first polynucleotide will hybridize to the same number of nucleobases or nucleotides in the contiguous sequence of the second polynucleotide. The contiguous sequence may include all or part of the first or second polynucleotide sequence.

[0117] As used herein, "partial complementarity" means that in a hybridizing pair of nucleobase sequences, at least 70% (but not all) of the bases in a contiguous sequence of a first polynucleotide will hybridize to the same number of bases in a contiguous sequence of a second polynucleotide.

[0118] As used herein, "substantially complementary" means that in a hybridization pair of nucleobase sequences, at least 85% (but not all) of the bases in the contiguous sequence of the first polynucleotide will hybridize to the same number of bases in the contiguous sequence of the second polynucleotide. The terms "complementary", "completely complementary", "partially complementary" and "substantially complementary" as used herein are used with respect to the nucleobases or nucleotides that match between the sense strand and the antisense strand of the RNAi agent or between the antisense strand of the RNAi agent and the sequence of the AAT mRNA.

[0119] As used herein, the term "substantially identical" or "substantially identical" for nucleic acid sequences means comprising nucleic acid sequences having at least about 85% sequence identity or more (e.g., at least 90%, at least 95%, or at least 99%) compared to a reference sequence. The percentage of sequence identity is determined by comparing the two optimally aligned sequences in the comparison window. The percentage is calculated as follows: the number of matching positions is generated by determining the number of positions where the same nucleic acid base appears in the two sequences, the number of matching positions is divided by the total number of positions in the comparison window, and the result is multiplied by 100 to generate the percentage of sequence identity. The invention disclosed herein encompasses nucleotide sequences that are substantially identical to those disclosed herein.

[0120] As used herein, the terms "treat," "treatment," and the like refer to methods or steps taken to provide relief or lessen the amount, severity, and / or frequency of symptoms of one or more diseases in a subject. As used herein, "treat" and "treatment" may include preventing, controlling, prophylactic treatment, and / or inhibiting the amount, severity, and / or frequency of symptoms of one or more diseases in a subject.

[0121] As used herein, when referring to RNAi substances, the phrase "introducing into cells" means functional delivery of RNAi substances into cells. The phrase "functional delivery" means delivering RNAi substances to cells in such a manner that the RNAi substances have the desired biological activity, for example, sequence-specific inhibition of gene expression.

[0122] Unless otherwise specified, the symbols used in this article are It means that it can be linked to one or more any groups according to the scope of the invention described herein.

[0123] As used herein, the term "isomer" refers to compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or in the spatial arrangement of their atoms. Isomers that differ in the spatial arrangement of their atoms are called "stereoisomers". Stereoisomers that are not mirror images of each other are called "diastereomers", and isomers that are non-superimposable mirror images are called "enantiomers" or sometimes optical isomers. A carbon atom to which four non-identical substituents are attached is called a "chiral center".

[0124] As used herein, unless a certain configuration is specifically indicated in the structure, for each structure where an asymmetric center exists and thus produces enantiomers, diastereomers or other stereoisomeric configurations, each structure disclosed herein is intended to represent all such possible isomers, including optically pure and racemic forms thereof. For example, the structures disclosed herein are intended to include mixtures of diastereomers as well as single stereoisomers.

[0125] The phrase "consisting of" as used in the claims herein excludes any elements, steps or ingredients not specified in the claim. When used in the claims herein, the phrase "consisting essentially of" limits the scope of the claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention.

[0126] Depending on the environment in which the compound or composition is located, one of ordinary skill in the art will readily understand and appreciate that the compounds and compositions disclosed herein may have certain atoms (e.g., N, O, or S atoms) in a protonated or deprotonated state. Thus, as used herein, it is contemplated that certain functional groups, such as OH, SH, or NH, of the structures disclosed herein may be protonated or deprotonated. As one of ordinary skill in the art will readily appreciate, the disclosure herein is intended to encompass the disclosed compounds and compositions, regardless of their protonation state based on the environment (e.g., pH).

[0127] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art are generally understood. Although methods and materials similar to or equivalent to those described herein may be used in the implementation or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference in their entirety. In the event of a conflict, this specification (including definitions) shall prevail. In addition, materials, methods and embodiments are illustrative only and are not intended to be limiting.

[0128] Other objects, features, aspects and advantages of the present invention will become apparent from the following detailed description, the accompanying drawings and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0129] Figures 1A-1E The chemical duplex structure of AD04828 shown as the sodium salt is shown.

[0130] Figure 2A-2E The chemical duplex structure of AD04828 shown as the free acid is shown.

[0131] Figures 3A-3E The chemical duplex structure of AD04831 shown as the sodium salt is shown.

[0132] Figures 4A-4E The chemical duplex structure of AD04831 shown as the free acid is shown.

[0133] Figures 5A-5E The chemical duplex structure of AD04836 shown as the sodium salt is shown.

[0134] Figures 6A-6E The chemical duplex structure of AD04836 shown as the free acid is shown.

[0135] Figures 7A-7E The chemical duplex structure of AD04837 shown as the sodium salt is shown.

[0136] Figures 8A-8E The chemical duplex structure of AD04837 shown as the free acid is shown.

[0137] Fig. 9 Is a bar graph showing mean normalized cyno AAT (cAAT) serum levels in cynomolgus monkeys (n=3) following a single subcutaneous administration of 3 mg / kg of AD04824, AD04825, AD04826 or AD04827 of Example 4. AAT serum levels were normalized to the pre-treatment mean. Experimental error is shown as standard deviation.

[0138] Fig.10 is a bar graph showing mean normalized cAAT serum levels in cynomolgus monkeys (n=2 or n=3) following a single subcutaneous administration of 3 mg / kg of AD04828, AD04836, AD04831 or AD04837 of Example 5. AAT serum levels were normalized to the pre-treatment mean. Experimental error is shown as standard deviation.

[0139] Fig.11 It is a bar graph showing the results of western blot analysis of the soluble fraction (Z-AAT monomer) of the liver of PiZ mice given saline or NAG-coupled AAT RNAi material with duplex structure AD04837 (Example 7) once every two weeks (q2w) for 8 weeks, normalized to baseline control. Individual mouse measurements are grouped by treatment group and experimental error is shown as standard deviation.

[0140] Fig.12 It is a bar graph showing the results of western blot analysis of the insoluble fraction (Z-AAT polymer) from the liver of PiZ mice given saline or NAG-coupled AAT RNAi material having a duplex structure AD04837 (Example 7). The individual mouse measurements are shown grouped by treatment group, and the experimental error is shown as standard deviation. DETAILED DESCRIPTION

[0141] RNAi substances

[0142] RNAi materials (referred to herein as AAT RNAi materials or AAT RNAi initiators) for inhibiting ATT gene expression are described herein. Each AAT RNAi material comprises a sense strand and an antisense strand. The length of the sense and antisense strands can be 16-30 nucleotides respectively. In some embodiments, the length of the sense and antisense strands can be 17-26 nucleotides respectively. The length of the sense and antisense strands can be the same or they can be different. In some embodiments, the length of the sense and antisense strands is 17-21 nucleotides each independently. In some embodiments, the length of the sense and antisense strands is 21-26 nucleotides each. In some embodiments, the length of the sense and antisense strands is 21-24 nucleotides each. In some embodiments, the length of the sense strand is about 19 nucleotides, and the length of the antisense strand is about 21 nucleotides. In some embodiments, the length of the sense strand is about 21 nucleotides, and the length of the antisense strand is about 23 nucleotides. In some embodiments, the length of the sense strand is 23 nucleotides, and the length of the antisense strand is 21 nucleotides. In some embodiments, the length of sense and antisense strands is 21 nucleotides each. In some embodiments, the length of sense strand is 22 nucleotides, and the length of antisense strand is 21 nucleotides. In some embodiments, the length of sense strand is 19 nucleotides, and the length of antisense strand is 21 nucleotides. In some embodiments, the length of RNAi material sense and antisense strand is 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides each independently. In some embodiments, double-stranded RNAi material has a duplex having a length of about 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides.

[0143] In some embodiments, the region of perfect or substantial complementarity between the sense and antisense strands is typically 16-26 (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26) nucleotides in length and occurs at or near the 5' end of the antisense strand (e.g., the region may be separated from the 5' end of the antisense strand by 0, 1, 2, 3, or 4 nucleotides that are not perfectly or substantially complementary).

[0144] The sense strand and the antisense strand each contain a core segment sequence of 16-23 nucleobases in length. The antisense strand core segment sequence is complementary to or has at least about 85% (substantially) complementarity with a nucleotide sequence present in the AAT mRNA target (sometimes referred to as, for example, a target sequence). The sense strand core segment sequence is 100% (perfectly) complementary to or has at least about 85% (substantially) complementarity with the core segment sequence in the antisense strand, so the sense strand core segment sequence is perfectly identical or at least about 85% identical to the nucleotide sequence (target sequence) present in the AAT mRNA target. The sense strand core segment sequence can be the same length as the corresponding antisense core segment sequence or it can be a different length. In some embodiments, the length of the antisense strand core segment sequence is 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides. In some embodiments, the length of the sense strand core segment sequence is 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides.

[0145] Examples of nucleotide sequences for forming AAT RNAi agents are provided in Tables 2, 3, 4, and 5. Table 6 shows examples of AAT RNAi agent duplexes comprising the sense and antisense strand sequences in Tables 2, 3, 4, and 5.

[0146] The sense and antisense strands of the AAT RNAi agent are usually annealed to form a duplex. The sense and antisense strands of the AAT RNAi agent may be partially, substantially or completely complementary to each other. In the complementary duplex region, the sense strand core segment sequence has at least 85% complementarity or 100% complementarity with the antisense strand core segment sequence. In some embodiments, the sense strand core segment sequence comprises a sequence of at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22 or at least 23 nucleotides having at least 85% or 100% complementarity with a 16, 17, 18, 19, 20, 21, 22 or 23 nucleotide sequence corresponding to the antisense strand core sequence (i.e., the sense and antisense core sequences of the AAT RNAi agent have a region of at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22 or at least 23 nucleotides having at least 85% base pairing or 100% base pairing).

[0147] In some embodiments, the antisense strand of the AAT RNAi agent disclosed herein differs from any antisense strand sequence in Table 2, Table 3, or Table 4 by 0, 1, 2, or 3 nucleotides. In some embodiments, the sense strand of the AAT RNAi agent disclosed herein differs from any sense strand sequence in Table 2, Table 3, or Table 5 by 0, 1, 2, or 3 nucleotides.

[0148] The sense strand and / or antisense strand may optionally and independently contain an additional 1, 2, 3, 4, 5 or 6 nucleotides (extensions) at the 3' end, 5' end, or both the 3' and 5' ends of the core segment sequence. The other nucleotides of the antisense strand, if present, may or may not be complementary to the corresponding sequence in the AAT mRNA. The other nucleotides of the sense strand, if present, may or may not be identical to the corresponding sequence in the AAT mRNA. The other nucleotides of the antisense strand, if present, may or may not be complementary to the other nucleotides of the corresponding sense strand (if present).

[0149] As used herein, extension includes 1, 2, 3, 4, 5 or 6 nucleotides at the 5' and / or 3' ends of the sense strand core segment sequence and / or the antisense strand core segment sequence. The extended nucleotides on the sense strand may or may not be complementary to the nucleotides in the corresponding antisense strand (whether core segment sequence nucleotides or extended nucleotides). Conversely, the extended nucleotides on the antisense strand may or may not be complementary to the nucleotides in the corresponding sense strand (whether core segment sequence nucleotides or extended nucleotides). In some embodiments, the sense strand and antisense strand of the RNAi material include 3' and 5' extensions. In some embodiments, one or more 3' extension nucleotides of a chain are base paired with one or more 5' extension nucleotides of another chain. In other embodiments, one or more 3' extension nucleotides of a chain are not base paired with one or more 5' extension nucleotides of another chain. In some embodiments, the antisense strand of the AAT RNAi material has a 3' extension and its sense strand has a 5' extension.

[0150] In some embodiments, the AAT RNAi agent comprises an antisense strand having a 3′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In other embodiments, the AAT RNAi agent comprises an antisense strand having a 3′ extension of 1, 2, or 3 nucleotides in length. In some embodiments, one or more antisense strand extension nucleotides comprise uracil or thymine nucleotides or nucleotides complementary to the corresponding AAT mRNA sequence. In some embodiments, the 3′ antisense strand extension comprises or consists of any of the following sequences, but is not limited to: AUA, UGCUU, CUG, UG, UGCC, CUGCC, CGU, CUU, UGCCUA, CUGCCU, UGCCU, UGAUU, GCCUAU, T, TT, U, UU (each shown as 5′→3′).

[0151] In some embodiments, the 3' end of the antisense strand may contain other abasic residues (Ab). "Abasic residues" or "abasic sites" are nucleotides or nucleosides that lack a nucleobase at the 1' position of the sugar. In some embodiments, Ab or AbAb may be added to the 3' end of the antisense strand. In some embodiments, one or more abasic residues may be added to the reverse abasic deoxyribose residue (invAb) (see Table 7), (see, e.g., F. Czauderna, Nucleic Acids Res., 2003, 31 (11), 2705-16).

[0152] In some embodiments, the AAT RNAi agent comprises a sense strand having a 3′ extension of 1, 2, 3, 4, or 5 nucleotides in length. In some embodiments, one or more sense strand extension nucleotides comprise adenosine, uracil, or thymine nucleotides, AT dinucleotides, or nucleotides corresponding to nucleotides in the AAT mRNA sequence. In some embodiments, the 3′ sense strand extension comprises or consists of any of the following sequences, but is not limited to: T, UT, TT, UU, UUT, TTT, or TTTT (each shown as 5′-3′).

[0153] In some embodiments, the 3' end of the sense strand may include other abasic residues (Ab). In some embodiments, UUAb, UAb or Ab are added to the 3' end of the sense strand. In some embodiments, the one or more abasic residues added to the 3' end of the sense strand are reverse (invAb). In some embodiments, one or more reverse abasic residues or abasic sites can be inserted between the core base sequence of the targeting ligand and the RNAi material sense strand. In some embodiments, one or more reverse abasic residues or abasic sites can be included in one or more ends of the RNAi material sense strand or near it to enhance the activity or other desired characteristics of the RNAi material.

[0154] In some embodiments, the AAT RNAi agent comprises a sense strand having a 5' extension of 1, 2, 3, 4, 5 or 6 nucleotides in length. In some embodiments, one or more sense strand extension nucleotides comprise uracil or adenosine nucleotides or nucleotides corresponding to nucleotides in the AAT mRNA sequence. In some embodiments, the sense strand 5' extension comprises or consists of any of the following sequences, but is not limited to: CA, AUAGGC, AUAGG, AUAG, AUA, A, AA, AC, GCA, GGCA, GGC, UAUCA, UAUC, UCA, UAU, U, UU (each shown as 5'-3'). The sense strand may have a 3' extension and / or a 5' extension.

[0155] In some embodiments, the 5' end of the sense strand may include one or more other abasic residues (e.g., (Ab) or (AbAb)). In some embodiments, the one or more abasic residues added to the 5' end of the sense strand may be reverse (e.g., invAb). In some embodiments, one or more reverse abasic residues may be inserted between the targeting ligand and the core base sequence of the RNAi substance sense strand. In some embodiments, including one or more reverse abasic residues at or near one or more ends of the RNAi substance sense strand can enhance the activity or other desired properties of the RNAi substance. In some embodiments, abasic (deoxyribose) residues may be substituted with ribitol (abasic ribose) residues.

[0156] In some embodiments, the 3′ end of the antisense strand core sequence or the 3′ end of the antisense strand sequence may contain an inverted abasic residue (invAb (see Table 7)).

[0157] Examples of sequences for forming AAT RNAi substances are provided in Tables 2, 3, 4, and 5. In some embodiments, the AAT RNAi substance antisense strand comprises a sequence shown in any of the sequences in Tables 2, 3, or 4. In some embodiments, the AAT RNAi substance antisense strand comprises a sequence shown in nucleotides (from 5' end → 3' end) 1-17, 2-15, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, or 2-24 of any of the sequences in Tables 2, 3, or 4. In certain embodiments, the AAT RNAi substance antisense strand comprises or consists of a modified sequence shown in any of the modified sequences in Table 4. In some embodiments, the AAT RNAi substance sense strand comprises a sequence shown in any of the sequences in Tables 2, 3, or 5. In some embodiments, the sense strand of the AAT RNAi agent comprises a sequence shown in nucleotides (from 5' end → 3' end) 1-18, 1-19, 1-20, 1-21, 1-22, 1-23, 1-24, 2-19, 2-20, 2-21, 2-22, 2-23, 2-24, 3-20, 3-21, 3-22, 3-23, 3-24, 4-21, 4-22, 4-23, 4-24, 5-22, 5-23, 5-24, 6-23, 6-24, 7-24 of any sequence in Table 2, 3 or 5. In certain embodiments, the sense strand of the AAT RNAi agent comprises or consists of a modified sequence shown in any modified sequence in Table 5.

[0158] In some embodiments, the sense and antisense strands of the RNAi material described herein contain the same number of nucleotides. In some embodiments, the sense and antisense strands of the RNAi material described herein contain different numbers of nucleotides. In some embodiments, the sense strand 5' end and the antisense strand 3' end of the RNAi material form a blunt end. In some embodiments, the sense strand 3' end and the antisense strand 5' end of the RNAi material form a blunt end. In some embodiments, both ends of the RNAi material form a blunt end. In some embodiments, neither end of the RNAi material is a blunt end. Blunt ends used herein refer to such ends of double-stranded RNAi materials, in which the terminal nucleotides of the two annealed chains are complementary (forming complementary base pairs).

[0159] In some embodiments, the 5′ end of the sense strand of the RNAi agent and the 3′ end of the antisense strand form a frayed end. In some embodiments, the 3′ end of the sense strand of the RNAi agent and the 5′ end of the antisense strand form a frayed end. In some embodiments, both ends of the RNAi agent form frayed ends. In some embodiments, neither end of the RNAi agent is a frayed end. As used herein, a frayed end refers to an end of a double-stranded RNAi agent in which the terminal nucleotides of the two annealed chains form a pair (i.e., do not form an overhang) but are not complementary (i.e., form a non-complementary pair). As used herein, an overhang is an extension of one or more unpaired nucleotides located at the end of one strand of a double-stranded RNAi agent. The unpaired nucleotides can be located at the sense strand or the antisense strand, producing a 3′ or 5′ overhang. In some embodiments, the RNAi agent comprises: a blunt end and a frayed end, a blunt end and a 5' overhang, a blunt end and a 3' overhang, a frayed end and a 5' overhang, a frayed end and a 3' overhang, two 5' overhangs, two 3' overhangs, a 5' overhang and a 3' overhang, two frayed ends, or two blunt ends.

[0160] When modified nucleotides are used in various polynucleotides or oligonucleotide constructs, they can maintain the activity of the compounds in cells while increasing the serum stability of these compounds, and can also minimize the possibility of activating interferon activity in humans after administration of the polynucleotides or oligonucleotide constructs.

[0161] In some embodiments, the AAT RNAi agent is prepared or provided in the form of a salt, a mixed salt, or a free acid. In some embodiments, the AAT RNAi agent is prepared as a sodium salt. Such forms are within the scope of the invention disclosed herein.

[0162] Modified nucleotides

[0163] In some embodiments, the AAT RNAi substance comprises one or more modified nucleotides. As used herein, "modified nucleotides" are nucleotides other than ribonucleotides (2'-hydroxy nucleotides). In some embodiments, at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100%) of the nucleotides are modified nucleotides. As used herein, modified nucleotides include, but are not limited to, deoxyribonucleotides, nucleotide mimics, abasic nucleotides (represented herein as Ab), 2'-modified nucleotides, 3' to 3' connecting (reverse) nucleotides (represented herein as invdN, invN, invn), nucleotides containing modified nucleobases, bridged nucleotides, peptide nucleic acids (PNA), 2', 3'-open ring nucleotide mimics (2', 3'-seco nucleotide mimics) (unlocked nucleobase analogs, represented herein as N UNA or NUNA), locked nucleotides (herein referred to as N LNA or NLNA), 3'-O-methoxy (2' internucleoside linked) nucleotides (represented herein as 3'-OMen), 2'-F-arabinonucleotides (represented herein as NfANA or Nf ANA 2'-modified nucleotides (i.e., nucleotides having a group other than a hydroxyl group at the 2' position of the five-membered sugar ring) include, but are not limited to, 2'-O-methyl nucleotides (represented herein by the lowercase letter "n" in the nucleotide sequence), 2'-deoxy-2'-fluoro nucleotides (represented herein by Nf, also represented herein by 2'-fluoro nucleotides), 2'-deoxy nucleotides (represented herein by dN), 2'-methoxyethyl (2'-O-2-methoxyethyl) nucleotides (represented herein by NM or 2'-MOE), 2'-amino nucleotides and 2'-alkyl nucleotides. It is not necessary to uniformly modify all positions in a given compound. Rather, more than one modification may be incorporated into a single AAT RNAi substance or even a single nucleotide thereof. The sense strand and antisense strand of the RNAi agent can be synthesized and / or modified by methods known in the art. The modification on one nucleotide is independent of the modification on another nucleotide.

[0164] Modified nucleobases include synthetic and natural nucleobases, such as: 5-substituted pyrimidines, 6-azapyrimidines, N-2, N-6 and O-6 substituted purines (e.g., 2-aminopropyladenine, 5-propynyluracil or 5-propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, inosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl (e.g., 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) derivatives of adenine and guanine, 2-propyl (e.g., 2-methyl, 2-ethyl, 2-isopropyl, or 2-n-butyl) and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halogenated Uracil, cytosine, 5-propynyluracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thio, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo (e.g., 5-bromo), 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

[0165] In some embodiments, the nucleotides of all or substantially all RNAi materials are modified nucleotides. As used herein, the RNAi materials wherein substantially all nucleotides present are modified nucleotides are RNAi materials having 4 or less (i.e., 0, 1, 2, 3 or 4) nucleotides in the (i.e., unmodified) sense strand and antisense strand as ribonucleotides. As used herein, the sense strand wherein substantially all nucleotides present are modified nucleotides are sense strands having 2 or less (i.e., 0, 1 or 2) nucleotides in the sense strand as ribonucleotides. As used herein, the antisense strand wherein substantially all nucleotides present are modified nucleotides are antisense strands having 2 or less (i.e., 0, 1 or 2) nucleotides in the sense strand as ribonucleotides. In some embodiments, one or more nucleotides of RNAi materials are ribonucleotides.

[0166] Modified internucleoside linkages

[0167] In some embodiments, one or more nucleotides of RNAi material are connected by non-standard connection or main chain (that is, modified internucleoside connection or modified main chain). Modified internucleoside connection or main chain include but are not limited to, 5'-phosphorothioate group (represented by lowercase "s" herein), chiral phosphorothioate, phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, alkylphosphonate (for example, methyl phosphonate or 3'-alkenylphosphonate), chiral phosphonate, phosphinate, phosphoramidate (for example, 3'-aminophosphoramidate, aminoalkylphosphoramidate, thiophosphoramidate), thioalkylphosphonate, thioalkylphosphotriester, morpholinyl connection, boron phosphate with normal 3'-5' connection, analog of boron phosphate 2'-5' connection or boron phosphate with reverse polarity (inverted polarity), wherein the adjacent pairs of nucleoside units are connected with 3'-5' to 5'-3' or 2'-5' to 5'-2'. In some embodiments, the internucleoside of modification is connected or the main chain lacks phosphorus atom.The internucleoside of modification lacking phosphorus atom is connected or the main chain includes but is not limited to, short chain alkyl or cycloalkyl sugar is connected, mixed heteroatoms and alkyl or cycloalkyl sugar are connected or one or more short chain heteroatoms or heterocyclic sugar are connected.In some embodiments, the internucleoside main chain of modification includes but is not limited to: siloxane main chain, sulfide main chain, sulfoxide main chain, sulfone main chain, formacetyl (formacetyl) and thioformyl main chain, methylene formacetyl and thioformyl acetyl main chain, containing alkene main chain, aminosulfonate main chain, methylene imino and methylene hydrazine main chain, sulfonate and sulfonamide main chain, amide main chain and have mixed N, O, S and CH2 other main chains of component.

[0168] In some embodiments, the sense strand of the AAT RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, the antisense strand of the AAT RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, or the sense strand and the antisense strand can independently contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages. In some embodiments, the sense strand of the AAT RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages, the antisense strand of the AAT RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages, or the sense strand and the antisense strand can independently contain 1, 2, 3, or 4 phosphorothioate linkages.

[0169] In some embodiments, the sense strand of the AAT RNAi substance contains at least 2 phosphorothioate nucleoside linkages. In some embodiments, at least 2 phosphorothioate nucleoside linkages are located between nucleotides at the 3' end position 1-3 of the sense strand. In some embodiments, at least 2 phosphorothioate nucleoside linkages are located between nucleotides at the 5' end position 1-3, 2-4, 3-5, 4-6, 4-5 or 6-8 of the sense strand. In some embodiments, the antisense strand of the AAT RNAi substance contains 4 phosphorothioate nucleoside linkages. In some embodiments, 4 phosphorothioate nucleoside linkages are located between nucleotides at the 5' end position 1-3 of the antisense strand and between nucleotides at the 5' end position 19-21, 20-22, 21-23, 22-24, 23-25 ​​or 24-26. In some embodiments, the AAT RNAi substance contains at least 2 phosphorothioate nucleoside linkages in the sense strand and 3 or 4 phosphorothioate nucleoside linkages in the antisense strand.

[0170] In some embodiments, the AAT RNAi agent comprises one or more modified nucleotides and one or more modified phosphorothioate internucleoside linkages. In some embodiments, 2' modified nucleotides are combined with modified internucleoside linkages.

[0171] AAT RNAi Substances

[0172] In some embodiments, the AAT RNAi agents disclosed herein target the AAT gene at or near the AAT genomic location shown in Table 1. In some embodiments, the antisense strand of the AAT RNAi agents disclosed herein comprises a core segment sequence that is completely, substantially, or at least partially complementary to the target AAT 19-mer sequence disclosed in Table 1.

[0173] Table 1. AAT 19-mer mRNA target sequence (taken from human AAT cDNA, GenBank NM_000295.4 (SEQ ID NO: 1))

[0174]

[0175]

[0176] In some embodiments, the AAT RNAi agent comprises an antisense strand, wherein position 19 (5′→3′) of the antisense strand is capable of forming a base pair with position 1 of a 19-mer target sequence disclosed in Table 1. In some embodiments, the AAT RNAi agent comprises an antisense strand, wherein position 1 (5′→3′) of the antisense strand is capable of forming a base pair with position 19 of a 19-mer target sequence disclosed in Table 1.

[0177] In some embodiments, the AAT RNAi agent comprises an antisense strand, wherein position 2 (5′→3′) of the antisense strand is capable of forming a base pair with position 18 of the 19-mer target sequence disclosed in Table 1. In some embodiments, the AAT RNAi agent comprises an antisense strand, wherein positions 2 to 18 (5′→3′) of the antisense strand are capable of forming a base pair with each corresponding complementary base located at positions 18 to 2 of the 19-mer target sequence disclosed in Table 1.

[0178] For the RNAi substances disclosed herein, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) may be perfectly complementary to the AAT gene, or may not be complementary to the AAT gene. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) is U, A or dT. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) forms an A:U or U:A base pair with the sense strand.

[0179] In some embodiments, the antisense strand of the AAT RNAi substance comprises a sequence of nucleotides 2-18 or 2-19 (from 5' end → 3' end) of any antisense strand sequence in Table 2, Table 3 or Table 4. In some embodiments, the positive strand of the AAT RNAi substance comprises a sequence of nucleotides 1-17, 1-18 or 2-18 (from 5' end → 3' end) of any positive strand sequence in Table 2, Table 3 or Table 5.

[0180] In some embodiments, the AAT RNAi substance comprises: (i) an antisense strand comprising a sequence of nucleotides 2-18 or 2-19 (from 5′ end → 3′ end) of any antisense strand sequence in Table 2, Table 3 or Table 4, and (ii) a sense strand comprising a sequence of nucleotides 1-17 or 1-18 (from 5′ end → 3′ end) of any sense strand sequence in Table 2, Table 3 or Table 5.

[0181] In some embodiments, the AAT RNAi agent comprises the core 19-mer nucleotide sequence shown in Table 2 below.

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198] The sense strand of the AAT RNAi agent comprising or consisting of the nucleotide sequence in Table 2 or Table 3 may be a modified nucleotide or an unmodified nucleotide. In some embodiments, the AAT RNAi agent having sense and antisense strands comprising or consisting of the nucleotide sequence in Table 2 or Table 3 are all or substantially all modified nucleotides.

[0199] In some embodiments, the antisense strand of the AAT RNAi agent disclosed herein differs from any antisense strand sequence in Table 2 or Table 3 by 0, 1, 2 or 3 nucleotides. In some embodiments, the sense strand of the AAT RNAi agent disclosed herein differs from any sense strand sequence in Table 2 or Table 3 by 0, 1, 2 or 3 nucleotides.

[0200] As used herein, each N in the disclosed sequences listed in Table 2 can be selected independently. In some embodiments, the N nucleotides in the disclosed sequences listed in Table 2 have such a core base that is complementary to the N nucleotides in the corresponding position on the other chain. In some embodiments, the N nucleotides in the disclosed sequences listed in Table 2 have such a core base that is not complementary to the N nucleotides in the corresponding position on the other chain. In some embodiments, the N nucleotides in the disclosed sequences listed in Table 2 have such a core base that is identical to the N nucleotides in the corresponding position on the other chain. In some embodiments, the N nucleotides in the disclosed sequences listed in Table 2 have such a core base that is different from the N nucleotides in the corresponding position on the other chain.

[0201] Tables 4 and 5 provide certain modified AAT RNAi agent sense and antisense strands. The modified AAT RNAi agent antisense strands and their potential unmodified nucleobase sequences are provided in Table 4. The modified AAT RNAi agent sense strands and their potential unmodified sequences are provided in Table 5. In forming the AAT RNAi agent, each nucleotide in each unmodified sequence listed in Tables 4 and 5 and Tables 2 and 3 above can be a modified nucleotide.

[0202] The AAT RNAi agent described herein is formed by annealing the antisense strand to the sense strand. A sense strand containing a sequence listed in Table 2, Table 3 or Table 5 can hybridize with any antisense strand containing a sequence listed in Table 2, Table 3 or Table 4, provided that the two sequences have a region of at least 85% complementarity over a continuous 16, 17, 18, 19, 20 or 21 nucleotide sequence.

[0203] In some embodiments, the antisense strand of the AAT RNAi agent comprises a nucleotide sequence shown in any one of Table 2, Table 3 or Table 4.

[0204] In some embodiments, the AAT RNAi agent comprises or consists of a duplex having a nucleobase sequence of a sense strand and an antisense strand of any sequence in Table 2 or Table 3.

[0205] Examples of antisense strands containing modified nucleotides are provided in Table 4. Examples of sense strands containing modified nucleotides are provided in Table 5.

[0206] As used in Tables 4 and 5, the following notations are used to indicate modified nucleotides, targeting groups, and linking groups. It is readily understood by one of ordinary skill in the art that, unless otherwise indicated by sequence, when present in an oligonucleotide, the monomers are interconnected by 5'-3'-phosphodiester bonds.

[0207]

[0208]

[0209] It is readily understood by those of ordinary skill in the art that the terminal nucleotide at the 3' end of a given oligonucleotide sequence will typically have a hydroxyl (-OH) group at the corresponding 3' position of a given monomer (rather than an isolated phosphate moiety). Unless otherwise expressly stated herein, this understanding of those of ordinary skill in the art is used when describing the AAT RNAi agents and compositions of AAT RNAi agents disclosed herein.

[0210] Targeting groups and linking groups include the following, whose chemical structures are provided in Table 7 below: (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), (NAG39)s. Each sense strand and / or antisense strand can have any of the targeting groups or linking groups listed above, as well as other targeting or linking groups coupled to the 5' and / or 3' end of the sequence.

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218] The AAT RNAi agent described herein is formed by annealing the antisense strand to the sense strand. A sense strand containing a sequence listed in Table 2, Table 3 or Table 5 can hybridize with any antisense strand containing a sequence listed in Table 2, Table 3 or Table 4, provided that the two sequences have a region of at least 85% complementarity over a continuous 16, 17, 18, 19, 20 or 21 nucleotide sequence.

[0219] In some embodiments, the antisense strand of the AAT RNAi agent disclosed herein differs from any antisense strand sequence in Table 4 by 0, 1, 2 or 3 nucleotides. In some embodiments, the sense strand of the AAT RNAi agent disclosed herein differs from any sense strand sequence in Table 5 by 0, 1, 2 or 3 nucleotides.

[0220] In some embodiments, the antisense strand of the AAT RNAi substance comprises a nucleotide sequence shown in any sequence in Table 2, Table 3 or Table 4. In some embodiments, the antisense strand of the AAT RNAi substance comprises a sequence shown in nucleotides (from 5' end → 3' end) 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24 or 2-24 of any sequence in Table 2, Table 3 or Table 4. In certain embodiments, the antisense strand of the AAT RNAi substance comprises or consists of a modified sequence shown in any modified sequence in Table 4.

[0221] In some embodiments, the sense strand of the AAT RNAi agent comprises a nucleotide sequence shown in any one of Tables 2, 3 or 5. In some embodiments, the sense strand of the AAT RNAi agent comprises a sequence shown in nucleotides (from 5' end → 3' end) 1-17, 2-17, 3-17, 4-17, 1-18, 2-18, 3-18, 4-18, 1-19, 2-19, 3-19, 4-19, 1-20, 2-20, 3-20, 4-20, 1-21, 2-21, 3-21, 4-21, 1-22, 2-22, 3-22, 4-22, 1-23, 2-23, 3-23, 4-23, 1-24, 2-24, 3-24 or 4-24 of any one of Tables 2, 3 or 5. In certain embodiments, the sense strand of the AAT RNAi agent comprises or consists of a modified sequence shown in any one of the modified sequences in Table 5.

[0222] For the AAT RNAi substances disclosed herein, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) may be perfectly complementary to the AAT gene, or may not be complementary to the AAT gene. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) is U, A or dT (or a modified form of U, A or dT). In some embodiments, the nucleotide at position 1 of the antisense strand (from 5' end → 3' end) forms an A:U or U:A base pair with the sense strand.

[0223] In some embodiments, the antisense strand of the AAT RNAi substance comprises a sequence of nucleotides 2-18 or 2-19 (from 5' end → 3' end) of any antisense strand sequence in Table 2, Table 3 or Table 4. In some embodiments, the positive strand of the AAT RNAi substance comprises a sequence of nucleotides 1-17 or 1-18 (from 5' end → 3' end) of any positive strand sequence in Table 2, Table 3 or Table 5.

[0224] In some embodiments, the AAT RNAi substance comprises: (i) an antisense strand comprising a sequence of nucleotides 2-18 or 2-19 (from 5′ end → 3′ end) of any antisense strand sequence in Table 2, Table 3 or Table 4, and (ii) a sense strand comprising a sequence of nucleotides 1-17 or 1-18 (from 5′ end → 3′ end) of any sense strand sequence in Table 2, Table 3 or Table 5.

[0225] A sense strand containing a sequence listed in Table 2, Table 3 or Table 5 can hybridize with any antisense strand containing a sequence listed in Table 2, Table 3 or Table 5, provided that the two sequences have a region of at least 85% complementarity over a continuous sequence of 16, 17, 18, 19, 20 or 21 nucleotides. In some embodiments, the AAT RNAi agent has a sense strand and an antisense strand, the sense strand consisting of a modified sequence of any modified sequence in Table 5, and the antisense strand consisting of a modified sequence of any modified sequence in Table 4. Representative sequence pairs are exemplified by the duplex ID sequences shown in Table 6.

[0226] In some embodiments, the AAT RNAi substance comprises any duplex represented by any duplex ID number shown herein. In some embodiments, the AAT RNAi substance consists of any duplex represented by any duplex ID number shown herein. In some embodiments, the AAT RNAi substance comprises the sense strand and antisense strand nucleotide sequences of any duplex represented by any duplex ID number shown herein. In some embodiments, the AAT RNAi substance comprises the sense strand and antisense strand nucleotide sequences of any duplex represented by any duplex ID number shown herein and a targeting group and / or a linking group, wherein the targeting group and / or the linking group are covalently linked (i.e., coupled) to the sense strand or the antisense strand. In some embodiments, the AAT RNAi substance comprises a modified nucleotide sequence of the sense strand and antisense strand of any duplex represented by any duplex ID number shown herein. In some embodiments, the AAT RNAi agent comprises a modified nucleotide sequence of the sense strand and antisense strand of any duplex represented by any duplex ID number shown herein and a targeting group and / or a linking group, wherein the targeting group and / or the linking group is covalently linked to the sense strand or the antisense strand.

[0227] In some embodiments, the AAT RNAi substance comprises an antisense strand and a sense strand having any antisense strand / sense strand duplex nucleotide sequence shown in Table 2, Table 3 or Table 6, and comprises an asialoglycoprotein receptor ligand targeting group.

[0228] In some embodiments, the AAT RNAi agent comprises an antisense strand and a sense strand having any one of the antisense strand / sense strand duplex nucleotide sequences shown in Table 2 or Table 5, and further comprises the following targeting groups: (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NA In some embodiments, the targeting group is (NAG25) or (NAG25)s as defined in Table 7. In other embodiments, the targeting group is (NAG37) or (NAG37)s as defined in Table 7.

[0229] In some embodiments, the AAT RNAi agent comprises an antisense strand and a sense strand having a modified nucleotide sequence of any antisense strand and / or sense strand nucleotide sequence of any duplex in Table 6.

[0230] In some embodiments, the AAT RNAi substance comprises an antisense strand and a sense strand, wherein the antisense strand and the sense strand have a modified nucleotide sequence of any antisense strand and / or sense strand nucleotide sequence of any duplex in Table 6, and comprise an asialoglycoprotein receptor targeting group.

[0231] In some embodiments, the AAT RNAi agent comprises a duplex structure of any duplex in Table 6.

[0232] In some embodiments, the AAT RNAi agent consists of a duplex structure of any duplex in Table 6.

[0233] Table 6. AAT RNAi species identified by duplex ID number and corresponding sense and antisense strands

[0234]

[0235]

[0236] In some embodiments, the AAT RNAi agent is prepared or provided in the form of a salt, mixed salts, or free acid. The RNAi agents described herein inhibit or knock down the in vivo expression of one or more AAT genes after delivery to cells expressing the AAT genes.

[0237] Targeting groups, linkers and delivery vehicles

[0238] In some embodiments, the AAT RNAi substance is coupled to one or more non-nucleotide groups, including but not limited to, a targeting group, a linking group, a delivery polymer or a delivery vehicle. The non-nucleotide group can enhance the targeting, delivery and connection of the RNAi substance. Table 7 provides examples of targeting groups and linking groups. The non-nucleotide group can be covalently linked to the 3' and / or 5' ends of the sense strand and / or antisense strand. In some embodiments, the AAT RNAi substance comprises a non-nucleotide group connected to the 3' and / or 5' ends of the sense strand. In some embodiments, the non-nucleotide group is connected to the 5' end of the sense strand of the AAT RNAi substance. The non-nucleotide group can be directly or indirectly connected to the RNAi substance via a joint / linking group. In some embodiments, the non-nucleotide group is connected to the RNAi substance via an unstable bond, a cleavable bond or a reversible bond or a joint.

[0239] In some embodiments, the non-nucleotide group can improve the pharmacokinetic or biodistribution properties of the conjugate or RNAi material to which it is attached to improve the cell or tissue-specific distribution and cell-specific uptake of the RNAi material or conjugate. In some embodiments, the non-nucleotide group enhances the endocytosis of the RNAi material.

[0240] Targeting group or targeting moiety can improve the pharmacokinetics or biodistribution characteristics of the conjugate or RNAi material of its engagement to improve the cell-specific distribution and cell-specific uptake of the conjugate or RNAi material. Targeting group can be monovalent, divalent, trivalent, tetravalent or have a higher valence state of the target directed to it. Representative targeting groups include but are not limited to, compounds with affinity to cell surface molecules, cell receptor ligands, half antibodies, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity to cell surface molecules. In some embodiments, the targeting group uses a joint to connect RNAi material, such as PEG joints or 1,2 or 4 abasic and / or ribitol (absorbic ribose) residues, which can be used as joints in some cases. In some embodiments, the targeting group includes a galactose derivative cluster.

[0241] The AAT RNAi agents described herein can be synthesized with a reactive group, such as an amine group, at the 5' end. The reactive group can be utilized for subsequent attachment of a targeting group using conventional methods in the art.

[0242] In some embodiments, the targeting group includes an asialoglycoprotein receptor ligand. In some embodiments, the asialoglycoprotein receptor ligand includes or is composed of one or more galactose derivatives. As used herein, the term galactose derivative includes galactose and a galactose derivative whose affinity for the asialoglycoprotein receptor is equal to or greater than that of galactose for its affinity. Galactose derivatives include, but are not limited to, galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butyryl-galactosamine and N-isobutyrylgalactosamine (see, for example, ST.Iobst and K.Drickamer, JBC, 1996, 271, 6686). Galactose derivatives and clusters of galactose derivatives that can be used to target oligonucleotides and other molecules to the liver in vivo are known in the art (see, e.g., Baenziger and Fiete, 1980, Cell, 22, 611-620; Connolly et al., 1982, J. Biol. Chem., 257, 939-945).

[0243] Galactose derivatives have been used to target molecules of hepatocytes in vivo through their joints with asialoglycoprotein receptors on the surface of hepatocytes. The engagement of asialoglycoprotein receptor ligands with one or more asialoglycoprotein receptors promotes cell-specific targeting of hepatocytes and the entry of endocytic molecules into hepatocytes. Asialoglycoprotein receptor ligands can be monomers (e.g., with a single galactose derivative) or polymers (e.g., with multiple galactose derivatives). Galactose derivatives or galactose derivative clusters can be used to engage the 3' or 5' end of the sense or antisense strand of RNAi substances using methods known in the art. The preparation of targeting groups such as galactose derivative clusters is described in, for example, U.S. Patent Application Serial No. 15 / 452,324 and U.S. Patent Publication No. US2017 / 0253875, and the contents of both are incorporated herein by reference in their entirety.

[0244] The galactose derivative cluster used herein comprises a molecule with 2-4 terminal galactose derivatives. The terminal galactose derivative is joined to a molecule by its C-1 carbon. In some embodiments, the galactose derivative cluster is a galactose derivative trimer (also referred to as a triantennary galactose derivative or a trivalent galactose derivative). In some embodiments, the galactose derivative cluster comprises N-acetyl-galactosamine. In some embodiments, the galactose derivative cluster comprises 3 N-acetyl-galactosamines. In some embodiments, the galactose derivative cluster is a galactose derivative tetramer (also referred to as a tetraantennary galactose derivative or a tetravalent galactose derivative). In some embodiments, the galactose derivative cluster comprises 4 N-acetyl-galactosamines.

[0245] As used herein, the galactose derivative trimer contains 3 galactose derivatives, each of which is connected to a central branch point. As used herein, the galactose derivative tetramer contains 4 galactose derivatives, each of which is connected to a central branch point. The galactose derivative can be connected to a central branch point by the C-1 carbon of the carbohydrate. In some embodiments, the galactose derivative is connected to a branch point by a joint or a spacer. In some embodiments, the joint or spacer is a flexible hydrophilic spacer, such as a PEG group (see, for example, U.S. Patent No. 5,885,968; Biessen et al., J.Med.Chem.1995 Volume 39 Pages 1538-1546). In some embodiments, the PEG spacer is a PEG3 spacer. The branch point can be any small molecule that allows the three galactose derivatives to bind, and also allows the branch point to bind RNAi substances. The example of a branch point group is dilysine or diglutamic acid. The engagement of the branch point with the RNAi substance can occur by a joint or a spacer. In some embodiments, the linker or spacer comprises a flexible hydrophilic spacer, such as but not limited to a PEG spacer. In some embodiments, the linker comprises a rigid linker, such as a cyclic group. In some embodiments, the galactose derivative comprises or is composed of N-acetyl-galactosamine. In some embodiments, the galactose derivative cluster comprises a galactose derivative tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.

[0246] Embodiments of the present disclosure include pharmaceutical compositions for delivering AAT RNAi substances to liver cells in vivo. Such pharmaceutical compositions include, for example, AAT RNAi substances coupled to galactose derivative clusters. In some embodiments, the galactose derivative clusters include galactose derivative trimers or tetramers, the galactose derivative trimers may be, for example, N-acetyl-galactosamine trimers, and the galactose derivative tetramers may be, for example, N-acetyl-galactosamine tetramers.

[0247] Targeting groups include, but are not limited to, (PAZ), (NAG13), (NAG13)s, (NAG18),

[0248] (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG 27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s , (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39) and (NAG39)s, as defined in Table 7. Other targeting groups are known in the art, including glass melt cluster targeting ligands.

[0249] In some embodiments, the linking group is coupled to the RNAi substance. The linking group promotes the covalent connection of the substance to the targeting group or the delivery polymer or the delivery vehicle. The linking group can connect the 3' or 5' end of the sense strand or antisense strand of the AAT RNAi substance. In some embodiments, the linking group is connected to the sense strand of the RNAi substance. In some embodiments, the linking group is coupled to the 5' or 3' end of the sense strand of the RNAi substance. In some embodiments, the linking group is coupled to the 5' end of the sense strand of the RNAi substance. Examples of linking groups include, but are not limited to, reactive groups such as primary amines and alkynes, alkyl groups, abasic nucleotides, ribitol (absorbic ribose) and / or PEG groups.

[0250] A linker or linking group is a connection between two atoms that connects a chemical group (such as an RNAi substance) or a segment of interest to another chemical group (such as a targeting group or a delivery polymer) or a segment of interest through one or more covalent bonds. Unstable connections include unstable bonds. The connection may optionally include a spacer that increases the distance between the two connected atoms. The spacer may also increase the flexibility and / or length of the connection. The spacer may include, but is not limited to, alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl; each of which may contain one or more heteroatoms, heterocycles, amino acids, nucleotides and sugars. Spacer groups are well known in the art, and the foregoing list is not intended to limit the scope of this description.

[0251] Any AAT RNAi agent nucleotide sequence listed in Table 2, 3, 4 or 5, whether modified or unmodified, may contain a 3' or 5' targeting group or linking group. Any AAT RNAi agent sequence listed in Table 4 containing a 3' or 5' targeting group or linking group may alternatively not contain a 3' or 5' targeting group or linking group, or may contain a different 3' or 5' targeting group or linking group, including but not limited to those shown in Table 7. Any AAT RNAi agent duplex listed in Table 2, Table 3 or Table 6, whether modified or unmodified, may further contain a targeting group or linking group, including but not limited to those shown in Table 7, and the targeting group or linking group may be joined to the 3' or 5' end of the sense strand or antisense strand of the AAT RNAi agent duplex.

[0252] Table 7 provides examples of targeting groups and linking groups. Table 5 provides various embodiments of the sense strand of an AAT RNAi agent having a targeting group or linking group attached to the 5' or 3' end.

[0253] Table 7. Structures representing various modified nucleotides, targeting groups, and linking groups

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272] In each of the above structures shown in Table 7, NAG comprises N-acetyl-galactosamine or another asialoglycoprotein receptor ligand, and the structures to be conjugated are within the scope of understanding of a person of ordinary skill in the art based on the above structures and descriptions provided herein. For example, in some embodiments, NAG in the structure provided in Table 7 is represented by the following structure:

[0273]

[0274] Each (NAGx) can be joined to the AAT RNAi agent via a phosphate group (as in (NAG25), (NAG30) and (NAG31)), or a phosphorothioate group (as in (NAG25)s, (NAG29)s, (NAG30)s, (NAG31)s or (NAG37)s) or other linking groups.

[0275]

[0276] Other linking groups known in the art may be used.

[0277] In some embodiments, a delivery vehicle can be used to deliver RNAi substances to cells or tissues. Delivery vehicles are compounds that improve the delivery of RNAi substances to cells or tissues. Delivery vehicles can include, but are not limited to, or consist of, but are not limited to, polymers, such as amphipathic polymers, membrane active polymers, peptides, melittin, melittin-like peptides (MLPs), lipids, reversibly modified polymers or peptides, or reversibly modified membrane active polyamines. In some embodiments, RNAi substances can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs, or other delivery systems accessible in the art. RNAi agents can also be chemically coupled to targeting groups, lipids (including but not limited to, cholesterol and cholesterol derivatives), nanoparticles, polymers, liposomes, micelles, DPC (see, e.g., 2000 / 053722, WO 2008 / 0022309, WO 2011 / 104169 and WO 2012 / 083185, WO 2013 / 032829, WO 2013 / 158141, each of which is incorporated herein by reference), or other delivery systems available in the art.

[0278] Pharmaceutical compositions and preparations

[0279] The AAT RNAi substances disclosed herein can be prepared as pharmaceutical compositions or pharmaceutical preparations. In some embodiments, the pharmaceutical composition contains an AAT RNAi substance. These pharmaceutical compositions can be particularly used to inhibit the expression of target mRNA in target cells, cell groups, tissues or organisms. The pharmaceutical composition can be used to treat subjects suffering from diseases or conditions that will benefit from a decrease in target mRNA levels or inhibition of target gene expression. The pharmaceutical composition can be used to treat such subjects, who are at risk of developing a disease or condition that will benefit from a decrease in target mRNA levels or inhibition of target gene expression. In one embodiment, the method comprises administering to the subject to be treated an AAT RNAi substance connected to a targeting ligand described herein. In some embodiments, one or more pharmaceutically acceptable excipients (including carriers, vehicles, diluents and / or delivery polymers) are added to a pharmaceutical composition comprising an AAT RNAi substance to form a pharmaceutical preparation suitable for in vivo delivery to a subject (including humans).

[0280] Pharmaceutical compositions comprising AAT RNAi agents and methods disclosed herein reduce the level of target mRNA in a cell, a group of cells, a cell population, a tissue or a subject, comprising: administering to a subject a therapeutically effective amount of the AAT RNAi agent described herein, thereby inhibiting the expression of AAT mRNA in the subject.

[0281] In some embodiments, the pharmaceutical compositions comprising AAT RNAi substances described herein are used to treat or manage clinical phenotypes of subjects with AATD, such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, elevated transaminases, cholestasis, fibrosis, and even fulminant hepatic failure. In some embodiments, a therapeutically or prophylactically effective amount of one or more pharmaceutical compositions is administered to a subject in need of such treatment. In some embodiments, administration of the disclosed AAT RNAi substances can be used to reduce the number, severity, and / or frequency of disease symptoms in a subject.

[0282] The pharmaceutical composition comprising an AAT RNAi substance can be used to treat at least one symptom in a subject suffering from a disease or condition that would benefit from reduction or inhibition of ATT mRNA expression. In some embodiments, a therapeutically effective amount of one or more pharmaceutical compositions comprising an AAT RNAi substance is administered to a subject, thereby treating the symptom. In other embodiments, a prophylactically effective amount of one or more AAT RNAi substances is administered to a subject, thereby preventing the at least one symptom.

[0283] The route of administration is the route by which the AAT RNAi material contacts the body. In general, methods of administering drugs and nucleic acids for treating mammals are well known in the art and can be used to administer the compositions described herein. The AAT RNAi materials disclosed herein can be administered via any suitable route in a preparation appropriately adjusted according to a particular route. Thus, the pharmaceutical compositions described herein can be administered by injection, for example, intravenous, intramuscular, intradermal, subcutaneous, intraduodenal or intraperitoneal injection. In some embodiments, the pharmaceutical compositions described herein are administered by subcutaneous injection.

[0284] Pharmaceutical compositions comprising AAT RNAi substances described herein can be delivered to cells, cell groups, tissues or objects using oligonucleotide delivery techniques that are suppressed in the art. In general, any suitable method for delivering nucleic acid molecules (in vitro or in vivo) recognized in the art can be applied to compositions described herein. For example, delivery can be by topical administration (e.g., direct injection, implantation or topical administration), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration. In some embodiments, compositions are administered by subcutaneous or intravenous infusion or injection.

[0285] Thus, in some embodiments, the pharmaceutical compositions described herein include one or more pharmaceutically acceptable excipients.The pharmaceutical compositions described herein can be formulated for administration to a patient.

[0286] As described herein, a pharmaceutical composition or medicament includes a pharmaceutically effective amount of at least one of the ATT RNAi substances and one or more pharmaceutically acceptable excipients. A pharmaceutically acceptable excipient (excipient) is a substance intentionally included in a drug delivery system in addition to an active pharmaceutical ingredient (API, therapeutic product, such as an AAT RNAi substance). The excipient does not promote or is not intended to promote the therapeutic effect at the intended dose. The excipient may play the following roles: a) assist in the processing of the drug delivery system during manufacturing; b) protect, support or improve the stability, bioavailability or patient acceptance of the API; c) assist in the identification of the product; and / or d) improve the overall safety and effectiveness of the delivery of the API during storage or use. Any other characteristics. A pharmaceutically acceptable excipient may or may not be an inert substance.

[0287] Excipients include, but are not limited to, absorption enhancers, anti-adherents, anti-foaming agents, antioxidants, binders, buffers, carriers, coatings, pigments, delivery enhancers, delivery polymers, polysaccharides, glucose, diluents, disintegrants, emulsifiers, expanders, fillers, flavoring agents, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickeners, isotonic agents, vehicles, waterproofing agents, and wetting agents.

[0288] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (when water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, The composition may be prepared in the form of ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). It should be stable under the conditions of manufacture and storage and should resist the contaminating action of microorganisms such as bacteria and fungi during storage. The carrier may be a solvent or dispersion medium comprising water, ethanol, a polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol) and suitable mixtures thereof. Suitable fluidity may be maintained, for example, by the use of a coating such as lecithin, by maintaining the desired particle size in the case of dispersions, and by the use of a surfactant. In many cases, it may be preferred to include an isotonic agent, for example, a sugar, a polyol such as mannitol, sorbitol, and sodium chloride in the composition. Substances that delay absorption (e.g., aluminum monostearate and gelatin) may be included in the composition to prolong the absorption of the injectable composition.

[0289] The required amount of active compound and one of the above components or a combination thereof can be mixed into a suitable solvent as needed and then filtered and sterilized to prepare a sterile injection. Usually, the active active substance is mixed into a sterile carrier containing an alkaline dispersion medium and the above other required ingredients to prepare a dispersion. In the case of sterile powders for preparing sterile injections, the preparation method includes vacuum drying and freeze drying to obtain a powder of the active component and any other required components obtained from a solution thereof that has been previously sterile filtered.

[0290] Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the drug, which may be in microcrystalline form, for example, as an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to present the drug for intra-articular and ophthalmic administration.

[0291] The active compound can be prepared in combination with a carrier that protects the compound from rapid clearance by the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared by methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0292] AAT RNAi substances can be formulated into unit dosage forms for ease of administration and uniform dosage. Unit dosage forms refer to physically discrete units used as single doses for the subject to be treated, each unit containing a predetermined amount of active compound and a desired pharmaceutical carrier, the predetermined amount being calculated to produce the desired therapeutic effect. The specifications of the dosage unit forms in the present disclosure depend on or are directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, as well as the inherent limitations in the field of synthesizing such active compounds for treating individuals.

[0293] The pharmaceutical composition may include other additional ingredients commonly used in pharmaceutical compositions. Other such components include, but are not limited to, antipruritic agents, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamines, diphenhydramine, etc.). It is also contemplated that cells, tissues, or separated organs expressing or comprising RNAi materials defined herein can be used as "pharmaceutical compositions". As described herein, "pharmaceutically effective amount", "therapeutically effective amount", or simply "effective amount" refers to the amount of RNAi materials that effectively produces the expected pharmaceutical, therapeutic, or preventive results.

[0294] Typically, the effective amount of the active compound will be in the range of about 0.1-about 100 mg / kg body weight / day, for example, about 1.0-about 50 mg / kg body weight / day. In some embodiments, the effective amount of the active compound will be in the range of about 0.25-about 5 mg / kg body weight for each dose. In some embodiments, the effective amount of the active ingredient will be in the range of about 0.5-about 4 mg / kg body weight for each dose. The amount administered may also depend on such variables as the overall health of the patient, the relative biological activity of the delivered compound, the formulation of the drug, the presence and type of excipients in the formulation, and the route of administration. In addition, it is understood that in some examples, the initial dose may exceed the above-mentioned higher levels to quickly achieve the desired blood level or tissue level, or in some examples, the initial dose may be less than the optimal value.

[0295] For the treatment of a disease or for the preparation of a drug or composition for treating a disease, the pharmaceutical composition comprising an AAT RNAi agent described herein can be combined with an excipient or with a second therapeutic agent or treatment including but not limited to the following: a second or other RNAi agent, a small molecule drug, an antibody, an antibody fragment, a peptide and / or an aptamer.

[0296] When added to a pharmaceutically acceptable excipient or adjuvant, the AAT RNAi substance can be packaged in a kit, container, bag or dispenser. The pharmaceutical composition described herein is packaged in a pre-filled syringe or bottle.

[0297] Treatment and methods of suppressing expression

[0298] The AAT RNAi substances disclosed herein can be used to treat subjects (e.g., humans or other mammals) suffering from diseases or conditions that would benefit from the administration of the compound. In some embodiments, the RNAi substances disclosed herein can be used to treat subjects (e.g., humans) suffering from AATD or diseases or conditions that would benefit from the reduction or inhibition of AAT mRNA expression (such as AATD liver disease). A therapeutically effective amount of any one or more AAT RNAi substances described herein is administered to the subject. The subject can be a human, a patient, or a human patient. The subject can be an adult, a teenager, a toddler, or an infant. The pharmaceutical compositions described herein comprising the AAT RNAi substances can be used to provide methods for therapeutic treatment of diseases such as AATD. Such methods include administering the pharmaceutical compositions described herein to humans or animals.

[0299] In some embodiments, the AAT RNAi substances described herein are used to treat a subject suffering from AATD (including symptoms, diseases or disorders associated with AATD). AATD liver diseases or disorders include, but are not limited to, chronic hepatitis, cirrhosis, hepatocellular carcinoma, elevated transaminases, cholestasis, fibrosis and fulminant liver failure. In some embodiments, the AAT RNAi substances are used to treat at least one symptom in a subject suffering from AATD. A therapeutically effective amount of any one or more of the RNAi substances is administered to a subject.

[0300] In certain embodiments, the present disclosure provides methods for treating AATD in a patient in need thereof, comprising administering to the patient any of the AAT RNAi agents described herein.

[0301] In some embodiments, the AAT RNAi agent is used to treat or control the clinical phenotype of a subject suffering from an AATD liver disease or condition. A therapeutically effective amount of any one or more AAT RNAi agents described herein or a composition comprising an AAT RNAi agent is administered to the subject. In some embodiments, the method comprises administering to the subject to be treated a composition comprising an AAT RNAi agent described herein.

[0302] In some embodiments, the gene expression level and / or mRNA level of the AAT gene in a subject administered the AAT RNAi agent is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or greater than 99% relative to a subject prior to administration of the AAT RNAi agent or a subject not receiving the AAT RNAi agent. The gene expression level and / or mRNA level in the subject is reduced in a cell, cell population and / or tissue of the subject.

[0303] In some embodiments, the protein level of AAT in a subject administered the AAT RNAi agent is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or greater than 99% relative to the subject prior to administration of the AAT RNAi agent or a subject not receiving the AAT RNAi agent. The protein level in the subject is reduced in a cell, cell population, tissue, blood, and / or other fluid of the subject.

[0304] In some embodiments, the protein level of Z-AAT polymer in a subject with AATD administered the AAT RNAi agent is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or greater than 99% relative to a subject prior to administration of the AAT RNAi agent or a subject that did not receive the AAT RNAi agent. In some embodiments, the protein level of Z-AAT polymer in a subject administered the AAT RNAi agent is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or greater than 99% relative to a subject prior to administration of the AAT RNAi agent or a subject that did not receive the AAT RNAi agent.

[0305] The reduction of AAT gene expression, AAT mRNA or AAT protein level can be evaluated and quantified by general methods known in the art. The embodiments disclosed herein are generally known methods for evaluating the inhibition of AAT gene expression and the reduction of AAT protein level. The reduction or decrease of AAT mRNA level and / or protein level (including Z-AAT polymers and / or monomers) is collectively referred to herein as the reduction or decrease of AAT or the inhibition or reduction of AAT expression.

[0306] Cells and tissues and non-human organisms

[0307] Cells, tissues, and non-human organisms comprising at least one AAT RNAi agent described herein are contemplated. Cells, tissues, or non-human organisms are produced by delivering the RNAi agent to the cell, tissue, or non-human organism.

[0308] The embodiments and items provided above are illustrated by the following non-limiting examples.

[0309] Example

[0310] Example 1. Identification of RNAi substance sequences and synthesis of RNAi substances

[0311] The selection process of identifying the guide sequence for inhibiting AAT gene expression starts with a computer simulation method to identify the conservative sequence of the AAT gene (SEQ ID NO: 1) variant. Initially, bioinformatics screening was used to screen the 19 nucleotide sequences with complementary sequences in known human AAT variants to screen out the AAT sequence. Sequences known to have manufacturing difficulties and sequences with poor RNAi activity based on known parameter predictions were excluded. The sequence was then subjected to species cross-reactivity analysis to select candidates that would cross antisense with cynomolgus macaque AAT. The specificity of the sequence was also evaluated to avoid off-target effects for human and cynomolgus macaque genomes. One hundred and fifteen (115) sequence families of 19 polymers were selected as candidates.

[0312] The duplexes in Table 6 herein were synthesized according to the following process:

[0313] synthesis

[0314] The sense and antisense strands of the RNAi agent are synthesized using the phosphoramidite technique on a solid phase for oligonucleotide synthesis. (Bioautomation) or (BioAutomation Corporation). In controlled pore glass (CPG, or The syntheses were performed on solid supports made from Prime Synthesis (Aston, PA, USA). All RNA and 2′-modified RNA phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, WI, USA). Specifically, the following 2′-O-methyl phosphoramidites were used: (5′-O-dimethoxytrityl-N 6 -(Benzoyl)-2′-O-methyl-adenosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite, 5′-O-dimethoxytrityl-N 4 -(acetyl)-2′-O-methyl-cytidine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite, (5′-O-dimethoxy-trityl-N 2-(isobutyryl)-2′-O-methyl-guanosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and 5′-O-dimethoxy-trityl-2′-O-methyl-uridine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite. 2′-Deoxy-2′-fluorophosphoramidites carry the same protecting groups as 2′-O-methyl RNA amides. The following UNA phosphoramidites were used: 5′-(4,4′-methoxytrityl)-N-benzoyl-2′,3′-secacaosine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, 5′-(4,4′-methoxytrityl)-N-acetyl-2′,3′-secacaosine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite )]-phosphoramidite, 5′-(4,4′-methoxytrityl)-N-isobutyryl-2′,3′-secouridine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, and 5′-(4,4′-dimethoxytrityl)-2′,3′-secouridine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite.

[0315] Targeting ligands containing phosphoramidites were dissolved in anhydrous dichloromethane or anhydrous acetonitrile (50 mM), while all other amidites were dissolved in anhydrous acetonitrile (50 mM) with the addition of molecular sieves. 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) was used as the activator solution. Coupling times were 10 min (RNA), 15 min (targeting ligand), 90 sec (2′OMe) and 60 sec (2′F). For phosphorothioate ligation, a 100 mM solution of 3-phenyl-1,2,4-dithiazolin-5-one (POS, obtained from PolyOrg, Inc., Leominster, MA, USA) in anhydrous acetonitrile was used. Cleavage and deprotection of oligomers bound to the support.

[0316] After completion of the solid phase synthesis, the dried solid support was treated with a 1:1 volume of 40 wt % methylamine solution and 28 % ammonium hydroxide solution (Aldrich) in water for 2 hours at 30° C. The solution was evaporated and the solid residue was reconstituted in water (see below).

[0317] purification

[0318] Crude oligomers were purified by anion exchange HPLC using a TKSgel SuperQ-5PW 13u column and a Shimadzu LC-8 system. Buffer A was 20 mM Tris, 5 mM EDTA, pH 9.0 and contained 20% acetonitrile and buffer B was the same as buffer A with 1.5 M sodium chloride added. UV traces were recorded at 260 nm. Appropriate fractions were pooled and then run on a size exclusion HPLC using a GE Healthcare XK 16 / 40 column filled with Sephadex G-25 media, with a running buffer of 100 mM ammonium bicarbonate, pH 6.7 and 20% acetonitrile.

[0319] annealing

[0320] Complementary chains are mixed to form RNAi materials by mixing equimolar solutions (sense and antisense) in 0.2×PBS (phosphate buffered saline, 1×, Corning, Cellgro). The solution is placed in a 70°C thermomixer, heated to 95°C, kept at 95°C for 5 minutes, and slowly cooled to room temperature. Some RNAi materials are lyophilized and stored at -15 to -25°C. The duplex concentration is determined by measuring the absorption of the solution on a UV-Vis spectrometer in 0.2×PBS. The duplex concentration is then determined by multiplying the absorption of the solution at 260nm by the conversion factor and the dilution factor. Unless otherwise stated, all conversion factors are 0.037mg / (mL·cm). For some experiments, the conversion factor was calculated from the experimentally determined extinction coefficient.

[0321] Example 2. In vitro testing of AAT RNAi substances

[0322] In vitro testing of candidate sequence duplexes. The antisense and sense strand sequences were annealed to form duplexes of 21-mer strands (with 19 base pairs and dinucleotide UU overhangs at each 3' end) for in vitro testing, as shown in Table 8 below.

[0323]

[0324]

[0325]

[0326]

[0327]

[0328] AAT RNAi agents were evaluated by transfecting Hep3B cells, which are a human hepatocellular carcinoma line. Cells were plated in a 96-well format at approximately 10,000 cells / well and each 115AAT RNAi agent duplex was transfected at 3 concentrations (10 nM, 1 nM, and 0.1 nM) using LipoFectamine RNAiMax (Thermo Fisher) transfection reagent. The relative expression of each 115AAT RNAi agent was determined by qRT-PCR by comparing the expression level of AAT mRNA with the endogenous control and normalized to untreated Hep3B cells (ΔΔC T Analysis), as shown in Table 9.

[0329] Table 9. In vitro data of duplexes of Example 2

[0330]

[0331]

[0332]

[0333]

[0334]

[0335] Example 3. In vivo testing of NAG-coupled AAT RNAi agents in PiZ mice

[0336] The transgenic Piz mouse model (PiZ mouse) is used to evaluate AAT RNAi agents in vivo. PiZ mice have a human PiZAAT mutant allele and mimic human AATD (Carlson et al., Journal of Clinical Investigation 1989).

[0337] AAT RNAi materials coupled to NAG were prepared in a pharmaceutically acceptable saline solution and administered to Piz mice to evaluate knockdown of AAT gene expression. On day 1, the dorsal loose skin between the shoulders of each mouse received a single subcutaneous (SQ) dose of 5.0 mg / kg (mpk) of AD04446, AD04447, AD04448, AD04449, AD04450, AD04451, AD04454, AD04455, AD04456, AD04457, AD04458 or AD04459. (See, modified AAT RNAi materials and NAG ligand structures in Tables 4-7). AAT RNAi substances AD04451 and AD04459 comprise a modified nucleotide antisense strand sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000; AAT RNAi substances AD04446 and AD04454 comprise a modified nucleotide antisense strand sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1142; AAT RNAi substances AD04447 and AD04455 comprise a modified nucleotide antisense strand sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1211; AAT RNAi substances AD04448 and AD04456 comprise a modified nucleotide antisense strand sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1326; AAT RNAi substances AD04449 and AD04457 comprise a modified nucleotide antisense strand sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1338; and AAT RNAi substances AD04450 and AD04458 comprise modified nucleotide antisense strand sequences designed to target the AAT gene (SEQ ID NO: 1) at position 1427. (See also Tables 1 and 2) Three mice were each administered the AAT RNAi substance (n=3).

[0338] Plasma samples were collected and analyzed for AAT (Z-AAT) protein levels on Day 1 (pre-dose), Day 8, Day 15, Day 22, Day 29, and Day 36. AAT levels were normalized to AAT plasma levels on Day 1 (pre-dose). Protein levels were measured by quantifying circulating human Z-AAT levels in plasma using a commercially available ELISA kit according to the manufacturer's recommendations. The average normalized AAT (Z-AAT) levels for each RNAi agent are shown in Table 10 below:

[0339]

[0340]

[0341] As shown in the data in Table 10 above, while the AAT RNAi substance AD04447 showed substantially no reduction in AAT protein, the AAT RNAi substances AD04458 (which comprised a modified nucleotide sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1427) and AD04459 (which comprised a modified nucleotide sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000) showed significant reductions in AAT protein at all time points. For example, AD04458 showed a knockdown of about 69% on day 8 (0.308); a knockdown of about 83% on day 15 (0.174); and a knockdown of about 82% on day 22 (0.177). In addition, for example, AD04459 showed about 74% knockdown on day 8 (0.256), about 87% knockdown on day 15 (0.134), and about 83% knockdown on day 22 (0.174).

[0342] Example 4. In vivo testing of NAG-coupled AAT RNAi agents in cynomolgus monkeys

[0343] NAG-coupled AAT RNAi materials were made and combined with pharmaceutically acceptable buffers known in the art for subcutaneous (SC) injection. On day 1, cynomolgus macaques (Macaca fascicularis) primates (referred to herein as "macaques" or "monkeys") were injected subcutaneously with 3 mg / kg of AD04824, AD04825, AD04826, or AD04827 (see modified AAT RNAi materials and NAG ligand structures in Tables 4-7). Each of these AAT RNAi materials contained a modified nucleotide sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000 and cross-reacted with macaques. Three monkeys (n=3) were tested in each group.

[0344] The serum samples of the cynomolgus macaques treated were collected at -7 days and the 1st day (before administration) and at the 8th, 15th, 22nd and 29th days to monitor the knockout. The macaques injected with AD04825 and AD04826 were also measured on the 36th day. At the specified time point, blood samples were collected and the cynomolgus macaque AAT (cAAT) was analyzed. Blood was collected by femoral vein. The cAAT level was measured at Cobas Integra 400 plus (Roche Diagnostics) according to the manufacturer's recommendation. The AAT level at each animal's corresponding time point was divided by the pretreatment level (mean value (before administration) of the animal's expression at -7 days and the 1st day) to determine the ratio of the expression of "standardization before administration".

[0345] The normalized cynomolgus macaque AAT (Z-AAT) protein levels after treatment with each corresponding RNAi substance are shown in the following Table 11:

[0346]

[0347] The mean normalized cAAT levels for each corresponding treatment group are shown in Fig. 9 As shown in Table 11 and Fig. 9 As shown, each AAT RNAi agent tested showed significant knockdown of cAAT at all time points measured in cynomolgus monkeys.

[0348] Example 5. In vivo testing of NAG-coupled AAT RNAi agents in cynomolgus monkeys

[0349] NAG-coupled AAT RNAi agents were made and combined with pharmaceutically acceptable buffers known in the art for subcutaneous (SC) injection. On day 1, cynomolgus macaques (Macaca fascicularis) primates were injected subcutaneously with 3 mg / kg of AD04828, AD04831, AD04836, or AD04837 (see modified AAT RNAi agents and NAG ligand structures in Tables 4-7). Each of these AAT RNAi agents contained a modified nucleotide sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000 and cross-reacted with macaques. Three monkeys in each group (n=3) were tested against AD04828 and AD04831, while two monkeys in each group (n=2) were tested against AD04836 and AD04837.

[0350] Serum samples of the treated macaques were collected on days -35 and 1 (before administration) and on days 8, 15, 21 and 29 to monitor knockout. At the specified time points, blood samples were collected and cAAT was analyzed. Blood was collected from the femoral vein. The cAAT level was measured on Cobas Integra400 plus (Roche Diagnostics) according to the manufacturer's recommendation. The cAAT level at the corresponding time point of each animal was divided by the pretreatment level expressed by the animal (the average value of day -35 and day 1 (before administration)) to determine the ratio of expression "standardized for pretreatment".

[0351] The normalized cynomolgus macaque AAT (Z-AAT) protein levels after treatment with each corresponding RNAi substance are shown in the following Table 12:

[0352]

[0353] The mean normalized cAAT levels for each corresponding treatment group are shown in Fig.10 As shown in Table 12 and Fig.10As shown in the middle bars, each AAT RNAi agent tested showed significant knockdown of cAAT at all time points measured in cynomolgus monkeys.

[0354] Example 6. In vivo testing of NAG-coupled AAT RNAi agents in PiZ mice

[0355] The transgenic PiZ mouse model (PiZ mouse) shown in Example 3 was used to evaluate AAT RNAi substances in vivo. AAT RNAi substances coupled to NAG were prepared with pharmaceutically acceptable saline and administered to Piz mice to evaluate the knockdown of AAT gene expression. On day 1, the dorsal loose skin between the shoulders of each mouse received a single subcutaneous (SQ) dose of 2.0 mg / kg (mpk) of AD04824, AD04828, AD04829, AD04830, AD04831, AD04832, AD04833, AD04834, AD04836, AD04837, AD04838, AD04839 or AD04857. (See, modified AAT RNAi substances and NAG ligand structures in Tables 4-7). The AAT RNAi substances in this study each comprise a modified nucleotide sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000. (See also Tables 1 and 2.) Three mice were each administered the AAT RNAi substance (n=3).

[0356] Plasma samples were collected and analyzed for AAT (Z-AAT) protein levels on Day -2, Day 1 (pre-dose), Day 8, Day 15, Day 22, Day 29, and Day 36. AAT levels were normalized to Day 1 (pre-dose) AAT plasma levels. Protein levels were measured by quantifying circulating human Z-AAT levels in plasma using a commercially available ELISA kit according to the manufacturer's recommendations. The average normalized AAT (Z-AAT) levels for each RNAi agent are shown below.

[0357] Table 13:

[0358]

[0359]

[0360] As shown in the data in Table 13 above, each of the AAT RNAi agents showed significant reductions in AAT protein at least through day 29. For example, on day 15, each of the AAT RNAi agents tested achieved at least about 70% protein knockdown compared to pretreatment levels, with multiple groups achieving 90% or better knockdown.

[0361] Example 7. In vivo testing of NAG-coupled AAT RNAi agents in PiZ mice

[0362] The transgenic PiZ mouse model described in Example 3 was used. At the beginning of the study, each mouse was 5 weeks old. NAG-coupled AAT RNAi material was prepared in pharmaceutically acceptable saline and administered to PiZ mice to evaluate the knockdown of AAT gene expression. Starting from day 1, the dorsal loose skin between the shoulders of each mouse received a subcutaneous (SQ) dose q2w (i.e., injected once every two weeks for a total of 4 injections) of 4.0 mg / kg (mpk) of (1) saline vehicle; (2) AD04837 (see modified AAT RNAi material and NAG ligand structure in Table 4-7), which includes a modified nucleotide antisense strand sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000 as shown previously; or (3) NAG-coupled RNAi material, which RNAi material contains a nucleotide sequence targeting the HBV gene, used as a negative control. Single subcutaneous injections were performed on days 1, 15, 29, and 43 for saline vehicle, AAT RNAi, and HBV RNAi groups. Seven (7) mice were given saline vehicle q2w (Group 1); nine (9) mice were given AAT RNAi q2w (Group 2); and six (6) mice were given HBV RNAi q2w (Group 3). Mice in the three treatment groups were sacrificed on day 57 (13 weeks of age). In addition to the treatment groups, seven (7) mice were sacrificed in week 1 of the study (i.e., 5-week-old mice) to retain baseline controls.

[0363] For all groups, plasma samples were collected and analyzed for AAT (Z-AAT) protein levels on days 1 (pre-dose), 8, 15, 22, 29, and 36. Additional samples for the AAT RNAi agent group and the saline vehicle group were collected on days 43, 50, and 57. AAT levels were normalized to day 1 (pre-dose) AAT plasma levels. Protein levels were measured by quantifying circulating human Z-AAT levels in plasma using a commercially available ELISA kit according to the manufacturer's recommendations. Average normalized AAT (Z-AAT) levels for saline vehicle and each RNAi agent are shown in Table 14 below:

[0364]

[0365] As shown in Table 14 above, the HBV RNAi material successfully served as a negative control, showing essentially no AAT inhibition. In addition, the NAG-coupled AAT RNAi material (AD04837) achieved significant knockdown expression at all time points compared to saline and the HBV RNAi material negative control. In q2w dosing, the AAT RNAi material in Example 7 showed approximately 96% knockdown of AAT protein (0.040) on day 36, and maintained similar knockdown levels until day 57.

[0366] In addition to monitoring serum AAT levels, homogenized liver tissue from PiZ mice treated with NAG-coupled AAT RNAi agents (AD04837) was further analyzed to determine whether soluble Z-AAT (expected to be the main monomeric protein) and insoluble aggregates of Z-AAT (expected to be polymeric proteins) were effectively reduced. A modified western blotting protocol as known in the art and previously described was used to separate the soluble and insoluble Z-AAT fractions in an undenatured state (see, e.g., Mueller et al., Molecular Therapy, March 2012, 20(3):590-600).

[0367] Western blots were prepared to examine certain livers of sacrificed mice. Specifically, livers of (i) 6 baseline mice, (ii) 5 AAT RNAi material mice, and (iii) 4 saline mice were examined. (The gel used for western blot analysis included 15 wells). Animal samples for this western blot were randomly selected from each group. Fig.11 and 12 Shown are bar graphs of Z-AAT polymer and Z-AAT monomer levels as quantified by western blot analysis.

[0368] As shown in the monomeric protein level Fig.11 As shown in the bar graph of , each mouse given the AAT RNAi agent showed a significant decrease in AAT monomer protein at all time points when compared to the baseline, indicating significant gene inhibition. In addition, as shown in the Fig.12 As shown, animals treated with saline vehicle continued to have increased polymeric AAT burden after 8 weeks. In contrast, animals treated with AAT RNAi agents showed approximately a 50% reduction in polymeric burden over the course of 8 weeks compared to baseline (5-week-old) mice, indicating that administration of NAG-conjugated AAT RNAi agents (AD04837) can prevent and possibly reverse polymeric AAT protein production.

[0369] Example 8 In vivo testing of NAG-coupled AAT RNAi agents in PiZ mice

[0370] The transgenic PiZ mouse model described in Example 3 was used to evaluate RNAi agents in vivo. On day 1, each mouse received a single subcutaneous (SQ) dose of (1) saline; (2) 1.0 mg / kg of NAG-conjugated AAT RNAi agent AD04837 (which contains a modified antisense sequence designed to target the AAT gene (SEQ ID NO: 1) at position 1000); (3) 2.0 mg / kg of AD04837; (4) 4.0 mg / kg of AD04837; or (5) 8.0 mg / kg of AD04837. Four animals in Group 1 were dosed (saline), and all four animals were sacrificed on day 43. Fifteen (15) animals in Groups 2, 3, 4, and 5 were dosed, and three animals in each group were sacrificed on days 8, 15, 22, 29, and 44, respectively.

[0371] For all groups, plasma samples were collected and analyzed for AAT (Z-AAT) protein levels on days 1 (pre-dose), 8, 15, 22, 29, 36, and 43. For mice sacrificed, cardiac support was performed to separate serum for Z-AAT protein level evaluation (200 μl plasma). AAT levels were standardized for AAT plasma levels on day 1 (pre-dose). Protein levels were measured by quantifying circulating human Z-AAT levels in plasma using a commercially available ELISA kit according to the manufacturer's recommendations. The average standardized AAT (Z-AAT) levels for saline vehicle and each RNAi agent administration group are shown in Table 15 below:

[0372]

[0373] As shown in Table 15 above, NAG-conjugated AAT RNAi agents achieved significant knockdown expression compared to saline at all time points at all dosing levels tested.

[0374] In addition, the AAT mRNA levels of the mice sacrificed were evaluated at each corresponding time point. As described above, for Groups 2 to 5 (i.e., RNAi material groups), 3 mice were sacrificed on each of Days 8, 15, 22, 29, and 43; and for Group 1, all 4 mice were sacrificed on Day 43. Half of the left liver lobe was collected and quickly frozen in liquid nitrogen for RNA isolation.

[0375] Table 16. Relative AAT mRNA levels in PiZ mice after a single SQ injection of saline or AAT RNAi agents

[0376]

[0377] As shown in Table 16 above, relative AAT mRNA expression levels were significantly reduced at all time points measured compared to saline vehicle. For example, at day 15, after a single SQ dose on day 1, Group 2 (1.0 mg / kg AAT RNAi agent) showed a decrease in AAT mRNA levels of approximately 58% (0.419); Group 3 (2.0 mg / kg AAT RNAi agent) showed a decrease in AAT mRNA levels of approximately 67% (0.327); Group 4 (4.0 mg / kg AAT RNAi agent) showed a decrease in AAT mRNA levels of approximately 84% (0.161); and Group 5 (8.0 mg / kg AAT RNAi agent) showed a decrease in Z-AAT mRNA levels of approximately 94% (0.055).

[0378] Other Implementations

[0379] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the appended claims.

Claims

1. An RNAi substance for inhibiting the expression of alpha-1 antitrypsin (AAT) gene, wherein the RNAi substance comprises a sense strand and an antisense strand, wherein the antisense strand comprises nucleotides 2-18 of any antisense strand sequence in Table 2, Table 3 or Table 4, and wherein the sense strand is at least substantially complementary to the antisense strand.

2. An RNAi substance for inhibiting the expression of alpha-1 antitrypsin (AAT) gene, wherein the RNAi substance comprises a sense strand and an antisense strand, wherein the sense strand comprises nucleotides 2-18 of any sense strand sequence in Table 2, Table 3 or Table 5, and wherein the antisense strand is at least substantially complementary to the sense strand.

3. The RNAi substance according to claim 1, wherein The antisense strand comprises a nucleotide sequence of any antisense strand sequence in Table 2, Table 3 or Table 4.

4. The RNAi substance according to claim 2, wherein The sense strand comprises a nucleotide sequence of any antisense strand sequence in Table 2, Table 3 or Table 5.

5. The RNAi substance according to claim 1, wherein The sense strand comprises a nucleotide sequence of any sense strand sequence in Table 4, and the antisense strand comprises a nucleotide sequence of any antisense strand sequence in Table 5.

6. The RNAi substance according to any one of claims 1 to 5, wherein The RNAi agent comprises at least one modified nucleotide.

7. The RNAi substance according to claim 6, wherein The at least one modified nucleotide is selected from: 2′-O-methyl nucleotides, 2′-fluoro nucleotides, 2′-deoxy nucleotides, 2′,3′-open ring nucleotide mimetics, locked nucleotides, 2′-F-arabino nucleotides, 2′-methoxyethyl nucleotides, abasic nucleotides, ribitol, reverse nucleotides, reverse abasic nucleotides, reverse 2′-OMe nucleotides, reverse 2′-deoxy nucleotides, 2′-amino modified nucleotides, 2′-alkyl modified nucleotides, morpholino nucleotides, vinylphosphonate deoxyribonucleotides and 3′-OMe nucleotides.

8. The RNAi substance according to any one of claims 1 to 5, wherein The RNAi agent comprises at least one phosphorothioate internucleoside linkage.

9. The RNAi substance according to any one of claims 1 to 5, wherein The sense strand comprises at least one phosphorothioate internucleoside linkage.

10. The RNAi substance according to any one of claims 1 to 5, wherein The antisense strand comprises 1, 2, 3 or 4 phosphorothioate internucleoside linkages.